## DEVELOPMENT OF RANIBIZUMAB, AN ANTI–VASCU BINDING FRAGMENT, AS THERAPY FOR NEOVASCULA

Retina

26, 859-870

DOI: 10.1097/01.iae.0000242842.14624.e7

**Citation Report** 

#	Article	IF	CITATIONS
1	Avastin and New Treatments for AMD: Where Are We?. Retina, 2006, 26, 853-858.	1.7	32
2	Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 3478-3483.	7.1	107
3	Antiangiogenic therapy for normalization of atherosclerotic plaque vasculature: a potential strategy for plaque stabilization. Nature Clinical Practice Cardiovascular Medicine, 2007, 4, 491-502.	3.3	104
4	Therapeutic effects of ranibizumab in neovascular age-related macular degeneration. Expert Review of Ophthalmology, 2007, 2, 679-693.	0.6	1
5	Transplantation in the treatment of age-related macular degeneration: past, present and future directions. Expert Review of Ophthalmology, 2007, 2, 497-511.	0.6	7
6	Targeting VEGF-A to Treat Cancer and Age-Related Macular Degeneration. Annual Review of Medicine, 2007, 58, 491-504.	12.2	227
7	Retinopathy of prematurity: is genetic predisposition an important risk factor?. Expert Review of Ophthalmology, 2007, 2, 275-283.	0.6	3
8	STANDARDIZED VISUAL ACUITY RESULTS ASSOCIATED WITH PRIMARY VERSUS SECONDARY BEVACIZUMAB (AVASTIN) TREATMENT FOR CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION. Retina, 2007, 27, 701-706.	1.7	39
9	Correspondence. Retina, 2007, 27, 1154-1156.	1.7	2
10	PREDICTED BIOLOGIC ACTIVITY OF INTRAVITREAL BEVACIZUMAB. Retina, 2007, 27, 1196-1200.	1.7	64
12	Correspondence. Retina, 2007, 27, 1154.	1.7	2
14	Antiangiogenic Therapy for Cancer: An Update. Cancer Journal (Sudbury, Mass ), 2007, 13, 345-348.	2.0	59
15	Ranibizumab According to Need: A Treatment for Age-related Macular Degeneration. American Journal of Ophthalmology, 2007, 143, 679-680.	3.3	223
16	Ultrastructural Findings in the Primate Eye After Intravitreal Injection of Bevacizumab. American Journal of Ophthalmology, 2007, 143, 995-1002.e2.	3.3	216
17	Treatment of Exudative Age-related Macular Degeneration: Many Factors to Consider. American Journal of Ophthalmology, 2007, 144, 281-283.	3.3	14
18	A potential therapeutic strategy for capillary hemangioma with new anti-vascular endothelial growth factor (anti-VEGF) agents. Medical Hypotheses, 2007, 69, 951.	1.5	0
19	Targeting Vascular Endothelial Growth Factor. Drugs and Aging, 2007, 24, 643-662.	2.7	43
20	A new era in the treatment of age-related macular degeneration: from Factor X to antiangiogenesis. Expert Opinion on Therapeutic Patents, 2007, 17, 1351-1363.	5.0	3

ITATION REDO

#	Article	IF	CITATIONS
21	Local Tolerance and Systemic Safety of Pegaptanib Sodium in the Dog and Rabbit. Journal of Ocular Pharmacology and Therapeutics, 2007, 23, 452-466.	1.4	37
22	Pegaptanib sodium for the treatment of ocular vascular disease. Expert Review of Ophthalmology, 2007, 2, 45-60.	0.6	1
23	Intravitreal Ranibizumab and Bevacizumab: A Review of Risk. Seminars in Ophthalmology, 2007, 22, 201-204.	1.6	60
25	Antiangiogenesis to treat cancer and intraocular neovascular disorders. Laboratory Investigation, 2007, 87, 227-230.	3.7	56
26	Intravitreal VEGF-inhibitors: is Avastin® a generic substitute for Lucentis®?. Acta Ophthalmologica, 2007, 85, 2-4.	0.3	17
27	Combination therapy for the treatment of ocular neovascularization. Angiogenesis, 2007, 10, 141-148.	7.2	106
28	Immunological mechanisms in the pathogenesis of diabetic retinopathy. Seminars in Immunopathology, 2008, 30, 65-84.	6.1	296
30	Current status of anti-vascular endothelial growth factor therapy in Europe. Japanese Journal of Ophthalmology, 2008, 52, 433-439.	1.9	26
31	Inhibition of proliferation, migration and tube formation of choroidal microvascular endothelial cells by targeting HIF-11± with short hairpin RNA-expressing plasmid DNA in human RPE cells in a coculture system. Graefe's Archive for Clinical and Experimental Ophthalmology, 2008, 246, 1413-1422.	1.9	35
32	Post-exposure targeting of specific epitopes on ricin toxin abrogates toxin-induced hypoglycemia, hepatic injury, and lethality in a mouse model. Laboratory Investigation, 2008, 88, 1178-1191.	3.7	38
33	Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer. Nature Reviews Cancer, 2008, 8, 309-316.	28.4	160
34	Modes of resistance to anti-angiogenic therapy. Nature Reviews Cancer, 2008, 8, 592-603.	28.4	2,603
35	Inhibitors of vascular endothelial growth factor (VEGF) in the management of neovascular ageâ€related macular degeneration: a review of current practice. Australasian journal of optometry, The, 2008, 91, 427-437.	1.3	60
36	Pegaptanib sodium for the treatment of age-related macular degeneration. Expert Opinion on Pharmacotherapy, 2008, 9, 499-508.	1.8	46
37	Ranibizumab for Macular Edema Due to Retinal Vein Occlusions: Implication of VEGF as a Critical Stimulator. Molecular Therapy, 2008, 16, 791-799.	8.2	291
38	Pathophysiology and Clinical Implications of Vascular Endothelial Growth Factor. , 2008, , 89-108.		0
39	Intravitreal Bevacizumab to Treat Iris Neovascularization and Neovascular Glaucoma Secondary to Ischemic Retinal Diseases in 41 Consecutive Cases. Ophthalmology, 2008, 115, 1571-1580.e3.	5.2	200
40	Vitreous Levels of Bevacizumab and Vascular Endothelial Growth Factor-A in Patients with Choroidal Neovascularization. Ophthalmology, 2008, 115, 1750-1755.e1.	5.2	153

#	Article	IF	CITATIONS
41	Time Course of Morphologic Effects on Different Retinal Compartments after Ranibizumab Therapy in Age-related Macular Degeneration. Ophthalmology, 2008, 115, e39-e46.	5.2	41
42	Anti–Vascular Endothelial Growth Factor Pharmacotherapy for Age-Related Macular Degeneration. Ophthalmology, 2008, 115, 1837-1846.	5.2	132
43	Safety Evaluation of Ocular Drug Delivery Formulations: Techniques and Practical Considerations. Toxicologic Pathology, 2008, 36, 49-62.	1.8	202
45	Development of Prodrug 4-Chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl Benzoate (TG100801): A Topically Administered Therapeutic Candidate in Clinical Trials for the Treatment of Age-Related Macular Degeneration, Journal of Medicinal Chemistry, 2008, 51, 1546-1559.	6.4	46
46	VEGF-induced effects on proliferation, migration and tight junctions are restored by ranibizumab (Lucentis) in microvascular retinal endothelial cells. British Journal of Ophthalmology, 2008, 92, 839-843.	3.9	53
48	Interaction between Bevacizumab and Murine VECF-A: A Reassessment. , 2008, 49, 522.		149
49	Combination of verteporfin photodynamic therapy and ranibizumab: effects on retinal anatomy, choroidal perfusion and visual function in the protect study. British Journal of Ophthalmology, 2008, 92, 1620-1627.	3.9	26
50	Automatic segmentation in three-dimensional analysis of fibrovascular pigmentepithelial detachment using high-definition optical coherence tomography. British Journal of Ophthalmology, 2008, 92, 197-203.	3.9	71
51	Progress and Prospects in Ocular Gene Therapy. , 2008, , 393-420.		0
52	Effects of Bevacizumab (Avastin) on Retinal Cells in Organotypic Culture. , 2008, 49, 3164.		38
53	Comparison of Bevacizumab, Ranibizumab, and Pegaptanib In Vitro: Efficiency and Possible Additional Pathways. , 2008, 49, 4523.		167
55	Repeat Administration of Proteins to the Eye With a Single Intraocular Injection of an Adenovirus Vector. Molecular Therapy, 2008, 16, 1444-1449.	8.2	7
57	COMBINATION PHOTODYNAMIC THERAPY AND INTRAVITREAL RANIBIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN A NORTH INDIAN POPULATION. Retina, 2008, 28, 1296-1301.	1.7	4
58	RANIBIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN FUNDUS FLAVIMACULATUS. Retinal Cases and Brief Reports, 2008, 2, 250-252.	0.6	6
59	COMBINATION PHOTODYNAMIC THERAPY AND INTRAVITREAL RANIBIZUMAB IN NEOVASCULAR AMD IN A NORTH INDIAN POPULATION. Retina, 2008, 28, 1132-1137.	1.7	10
60	Treatment of age-related macular degeneration: focus on ranibizumab. Clinical Ophthalmology, 2008, 2, 1.	1.8	40
61	Simultaneous but Not Prior Inhibition of VEGF165 Enhances the Efficacy of Photodynamic Therapy in Multiple Models of Ocular Neovascularization. , 2008, 49, 662.		20
62	Antiangiogênicos no glaucoma. Revista Brasileira De Oftalmologia, 2008, 67, 313-320.	0.1	Ο

#	Article	IF	CITATIONS
63	The Efficacy of Ranibizumab for Choroidal Neovascularization in Age-related Macular Degeneration. Journal of Korean Ophthalmological Society, 2009, 50, 725.	0.2	9
64	Evaluation of Ranibizumab-Induced Changes in High-Resolution Optical Coherence Tomographic Retinal Morphology and Their Impact on Visual Function. , 2009, 50, 2376.		61
65	VEGF-A: aÂcritical regulator ofÂblood vessel growth. European Cytokine Network, 2009, 20, 158-163.	2.0	281
66	Retinal Pigment Epithelium Differentiation of Stem Cells: Current Status and Challenges. Critical Reviews in Biomedical Engineering, 2009, 37, 355-375.	0.9	15
67	siRNA therapeutics for age-related macular degeneration: promises and pitfalls. Expert Review of Ophthalmology, 2009, 4, 525-535.	0.6	0
68	Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. , 2009, , CD007419.		61
69	Activated VEGF Receptor Shed Into the Vitreous in Eyes With Wet AMD. JAMA Ophthalmology, 2009, 127, 613.	2.4	37
70	Pegaptanib Sodium for Macular Edema Secondary to Central Retinal Vein Occlusion. JAMA Ophthalmology, 2009, 127, 374.	2.4	89
71	Treating Age-Related Macular Degeneration – Interaction of VEGF-Antagonists with their Target. Mini-Reviews in Medicinal Chemistry, 2009, 9, 1127-1135.	2.4	25
72	The effects of ranibizumab (Lucentis) on retinal function in isolated perfused vertebrate retina. British Journal of Ophthalmology, 2009, 93, 1396-1400.	3.9	15
73	Somatostatin analogues as therapeutics in retinal disease. , 2009, 122, 324-333.		22
74	Therapeutic monoclonal antibodies in ophthalmology. Progress in Retinal and Eye Research, 2009, 28, 117-144.	15.5	144
75	VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Current Opinion in Cell Biology, 2009, 21, 154-165.	5.4	636
76	Intravitreal ranibizumab (Lucentis®) for the treatment of myopic choroidal neovascularization. Graefe's Archive for Clinical and Experimental Ophthalmology, 2009, 247, 311-318.	1.9	65
77	Combinatory inhibition of VEGF and FGF2 is superior to solitary VEGF inhibition in an in vitro model of RPE-induced angiogenesis. Graefe's Archive for Clinical and Experimental Ophthalmology, 2009, 247, 767-773.	1.9	37
78	Different properties of VEGF-antagonists: Bevacizumab but not Ranibizumab accumulates in RPE cells. Graefe's Archive for Clinical and Experimental Ophthalmology, 2009, 247, 1601-1608.	1.9	59
79	VEGF inhibition: insights from preclinical and clinical studies. Cell and Tissue Research, 2009, 335, 261-269.	2.9	179
80	Intensified monitoring of circadian blood pressure and heart rate before and after intravitreous injection of bevacizumab: preliminary findings of a pilot study. International Ophthalmology, 2009, 29, 213-224	1.4	22

#	Article	IF	CITATIONS
81	Intravitreal bevacizumab (avastin) for subfoveal neovascular age-related macular degeneration. International Ophthalmology, 2009, 29, 349-357.	1.4	24
82	Local effects of the sphingosine 1â€phosphate on prostaglandin F2alphaâ€induced luteolysis in the pregnant rat. Molecular Reproduction and Development, 2009, 76, 1153-1164.	2.0	19
83	Proteins and Peptides. , 0, , .		5
84	Discovery of Potent and Practical Antiangiogenic Agents Inspired by Cortistatin A. Journal of the American Chemical Society, 2009, 131, 9014-9019.	13.7	57
85	Anti-sphingosine-1-phosphate monoclonal antibodies inhibit angiogenesis and sub-retinal fibrosis in a murine model of laser-induced choroidal neovascularization. Experimental Eye Research, 2009, 88, 367-377.	2.6	87
86	Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal dose range on endothelial cells. Experimental Eye Research, 2009, 88, 522-527.	2.6	57
87	Microincision Vitrectomy Surgery and Intravitreal Bevacizumab as a Surgical Adjunct to Treat Diabetic Traction Retinal Detachment. Ophthalmology, 2009, 116, 927-938.	5.2	163
88	Effects of Intraocular Ranibizumab and Bevacizumab in Transgenic Mice Expressing Human Vascular Endothelial Growth Factor. Ophthalmology, 2009, 116, 1748-1754.	5.2	36
89	Antiangiogenic Approaches to Age-Related Macular Degeneration Today. Ophthalmology, 2009, 116, S15-S23.	5.2	112
90	Prospective Study of Intravitreal Ranibizumab as a Treatment for Decreased Visual Acuity Secondary to Central Retinal Vein Occlusion. American Journal of Ophthalmology, 2009, 147, 298-306.	3.3	156
91	Ranibizumab for Refractory Uveitis-related Macular Edema. American Journal of Ophthalmology, 2009, 148, 303-309.e2.	3.3	74
92	Overview on Concepts and Applications of Fab Antibody Fragments. Current Protocols in Protein Science, 2009, 55, Unit 6.9.	2.8	21
93	Retinal Angiography and Optical Coherence Tomography. , 2009, , .		18
94	Long-term remission of myopic choroidal neovascular membrane after treatment with ranibizumab: a case report. Journal of Medical Case Reports, 2009, 3, 84.	0.8	5
95	The Effects of Intravitreal Ophthalmic Medications on Intraocular Pressure. Seminars in Ophthalmology, 2009, 24, 100-105.	1.6	21
96	Molecular pathology of age-related macular degeneration. Progress in Retinal and Eye Research, 2009, 28, 1-18.	15.5	498
97	Multiple effects of bevacizumab in angiogenesis: implications for its use in ageâ€related macular degeneration. Acta Ophthalmologica, 2009, 87, 517-523.	1.1	18
98	The absence of angiopoietin-2 leads to abnormal vascular maturation and persistent proliferative retinopathy. Thrombosis and Haemostasis, 2009, 102, 120-130.	3.4	21

#	Article	IF	CITATIONS
100	VERTEPORFIN COMBINATION REGIMENS IN THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2009, 29, 133-148.	1.7	30
101	PREPARATION, CHARACTERIZATION, AND IN VIVO EVALUATION OF NANOLIPOSOMES-ENCAPSULATED BEVACIZUMAB (AVASTIN) FOR INTRAVITREAL ADMINISTRATION. Retina, 2009, 29, 699-703.	1.7	150
102	INTRAVITREAL INJECTION OF THERAPEUTIC AGENTS. Retina, 2009, 29, 875-912.	1.7	215
103	INTRAVITREAL RANIBIZUMAB FOR CHOROIDAL NEOVASCULARIZATION COMPLICATING PATHOLOGIC MYOPIA. Retina, 2010, 30, 399-406.	1.7	68
104	More Questions Than Answers: A Call for a Moratorium on the Use of Intravitreal Infliximab Outside of a Well-Designed Trial. Retina, 2010, 30, 1-5.	1.7	41
105	SAFETY EVALUATION OF REPEATED INTRAVITREAL INJECTIONS OF BEVACIZUMAB AND RANIBIZUMAB IN RABBIT EYES. Retina, 2010, 30, 671-681.	1.7	34
107	Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. Graefe's Archive for Clinical and Experimental Ophthalmology, 2010, 248, 785-791.	1.9	96
108	Impact of injection techniques on intraocular pressure (IOP) increase after intravitreal ranibizumab application. Graefe's Archive for Clinical and Experimental Ophthalmology, 2010, 248, 1371-1375.	1.9	32
109	Effect of an intravitreal injection of bevacizumab on the expression of VEGF and CD34 in the retina of diabetic rats. Clinical and Experimental Ophthalmology, 2010, 38, 875-884.	2.6	15
110	Inhibitory efficacy of hypoxia-inducible factor 1α short hairpin RNA plasmid DNA-loaded poly (D,) Tj ETQq1 1 0.78 Gene Therapy, 2010, 17, 338-351.	4314 rgB1 4.5	7 /Overlock 42
111	Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy. Nature Medicine, 2010, 16, 1107-1111.	30.7	184
112	Treatment of retinal pigment epithelial detachment with antiangiogenic therapy. Clinical Ophthalmology, 2010, 4, 369.	1.8	20
113	Anatomical Non-Responder to Intravitreal Bevacizumab for Neovascular Age-Related Macular Degeneration. Journal of Korean Ophthalmological Society, 2010, 51, 1464.	0.2	4
114	Ocular angiogenesisvascular endothelial growth factor and other factors. , 2010, , 23-36.		1
115	Pegaptanib Sodium in the Treatment of Neovascular Age-Related Macular Degeneration. Clinical Medicine Insights Therapeutics, 2010, 2, CMT.S2393.	0.4	0
116	Pathological Retinal Angiogenesis. , 2010, , 280-289.		1
117	Inhibition of Protein Kinase C Is Not Sufficient to Prevent or Reverse Effects of VEGF <sub>165</sub> on Claudin-1 and Permeability in Microvascular Retinal Endothelial Cells. , 2010, 51, 535.		18
118	Paracrine Modulation of CXCR4 by IGF-1 and VEGF: Implications for Choroidal Neovascularization. , 2010, 51, 2697.		39

#	Article	IF	CITATIONS
119	Pathophysiology of vascular endothelial growth factor and other angiogenic molecules. , 2010, , 230-235.		0
120	Structural and mechanistic insight into how antibodies inhibit serine proteases. Biochemical Journal, 2010, 430, 179-189.	3.7	45
121	Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration. New England Journal of Medicine, 2010, 363, 1648-1655.	27.0	80
122	Alternative anti-VEGF treatment regimens in exudative age-related macular degeneration. Expert Review of Ophthalmology, 2010, 5, 799-809.	0.6	0
123	Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study). Diabetes Care, 2010, 33, 2399-2405.	8.6	656
124	Therapeutic monoclonal antibodies and fragmentsranibizumab. , 2010, , 226-229.		1
125	Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: the LEVEL study. British Journal of Ophthalmology, 2010, 94, 1611-1617.	3.9	44
126	Ocular safety profile and intraocular pharmacokinetics of an antagonist of EphB4/EphrinB2 signalling. British Journal of Ophthalmology, 2010, 94, 1668-1673.	3.9	8
127	Current Approaches to the Management of Diabetic Retinopathy and Diabetic Macular Oedema. Drugs, 2010, 70, 2171-2200.	10.9	34
128	Endothelial Heparan Sulfate in Angiogenesis. Progress in Molecular Biology and Translational Science, 2010, 93, 179-212.	1.7	70
129	Influence of Non-Toxic Doses of Bevacizumab and Ranibizumab on Endothelial Functions and Inhibition of Angiogenesis. Current Eye Research, 2010, 35, 835-841.	1.5	8
130	Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. British Journal of Ophthalmology, 2010, 94, 2-13.	3.9	262
131	Targeting retinal and choroid neovascularization using the small molecule inhibitor carboxyamidotriazole. Brain Research Bulletin, 2010, 81, 320-326.	3.0	10
132	Clinical Application of Therapies Targeting VEGF. Cell, 2010, 143, 13-16.	28.9	48
133	Pegaptanib Sodium for Macular Edema Secondary to Branch Retinal Vein Occlusion. American Journal of Ophthalmology, 2010, 149, 147-154.	3.3	57
134	EXTEND″: safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to ageâ€related macular degeneration. Acta Ophthalmologica, 2010, 88, 309-316.	1.1	45
135	The Role of Vascular Endothelial Growth Factor-Induced Activation of NADPH Oxidase in Choroidal Endothelial Cells and Choroidal Neovascularization. American Journal of Pathology, 2010, 177, 2091-2102.	3.8	45
137	Bevacizumab versus ranibizumab for the treatment of neovascular age-related macular degeneration. Expert Review of Ophthalmology, 2010, 5, 603-615.	0.6	1

ARTICLE IF CITATIONS # Comparing Treatment of Neovascular Age-related Macular Degeneration with Sequential Intravitreal Avastin and Macugen Versus Intravitreal Mono-therapy–A Pilot Study. Current Ėye Research, 2011, 36, 138 1.5 8 958-963. Neovascular Age-Related Macular Degeneration. BioDrugs, 2011, 25, 171-189. 4.6 Inhibition of vascular endothelial growth factor (VEGF) is sufficient to completely restore barrier 140 malfunction induced by growth factors in microvascular retinal endothelial cells. British Journal of 3.9 28 Ophthalmology, 2011, 95, 1151-1156. A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab. Current Medical Research and Opinion, 2011, 27, 1465-1475. 141 Arterial Thromboembolic Events in Patients with Exudative Age-Related Macular Degeneration Treated 142 1.9 51 with Intravitreal Bevacizumab or Ranibizumab. Ophthalmologica, 2011, 225, 211-221. Management of Neovascular AMD., 2011, , 79-98. The Future of Neovascular Age-Related Macular Degeneration., 2011, , 135-153. 144 1 Therapeutic Efficacy of Bevacizumab for Age-Related Macular Degeneration. Drugs and Aging, 2011, 28, 2.7 145 9 853-865. Drug Product Development for the Back of the Eye. AAPS Advances in the Pharmaceutical Sciences 146 0.6 13 Series, 2011, , . How the Comparison of Age-related Macular Degeneration Treatments Trial Results Will Impact 3.3 Clinical Care. American Journal of Ophthalmology, 2011, 152, 509-514. Comparing protein VEGF inhibitors: In vitro biological studies. Biochemical and Biophysical Research 148 2.1 82 Communications, 2011, 408, 276-281. Systemic and Ocular Safety of Intravitreal Anti-VEGF Therapies for Ocular Neovascular Disease. Survey 4.0 of Ophthalmology, 2011, 56, 95-113. Efficacy and Safety of Monthly versus Quarterly Ranibizumab Treatment in Neovascular Age-related 150 5.2 353 Macular Degeneration: The EXCITE Study. Ophthalmology, 2011, 118, 831-839. Safety and Efficacy of a Flexible Dosing Regimen of Ranibizumab in Neovascular Age-Related Macular 5.2 366 Degeneration: The SUSTAIN Study. Ophthalmology, 2011, 118, 663-671. Developmental and Pathological Angiogenesis. Annual Review of Cell and Developmental Biology, 2011, 152 620 9.4 27, 563-584. Longâ€term efficacy and safety of ranibizumab administered <i>pro re nata</i> in Japanese patients with neovascular ageâ&related macular degeneration in the EXTENDâ& study. Acta Ophthalmologica, 2011, 89, 1.1 208-217. The Effect of Triple Therapy on Patients with Subretinal Hemorrhage Accompanied by Choroidal 155 0.2 0 Neovascularization. Journal of Korean Ophthalmological Society, 2011, 52, 442. The effect of intravitreal bevacizumab (Avastin®) on ocular pulse amplitude in neovascular 1.8 age-related macular degeneration. Clinical Ophthalmology, 2011, 5, 37.

#	Article	IF	CITATIONS
157	Retinal vein occlusion and macular edema – critical evaluation of the clinical value of ranibizumab. Clinical Ophthalmology, 2011, 5, 771.	1.8	15
158	Management of Neovascular Age-Related Macular Degeneration in Clinical Practice: Initiation, Maintenance, and Discontinuation of Therapy. Journal of Ophthalmology, 2011, 2011, 1-10.	1.3	5
159	One-Year Outcomes Using Ranibizumab for Neovascular Age-Related Macular Degeneration: Results of a Prospective and Retrospective Observational Multicentre Study. Journal of Ophthalmology, 2011, 2011, 1-8.	1.3	46
160	Treatment of macular edema due to retinal vein occlusions. Clinical Ophthalmology, 2011, 5, 705.	1.8	33
161	LONGER-TERM OUTCOMES OF A PROSPECTIVE STUDY OF INTRAVITREAL RANIBIZUMAB AS A TREATMENT FOR DECREASED VISUAL ACUITY SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION. Retina, 2011, 31, 821-828.	1.7	20
162	Combined Treatment Modalities for Age Related Macular Degeneration. Current Drug Targets, 2011, 12, 182-189.	2.1	11
163	Anti-VEGF Compounds in the Treatment of Neovascular Age Related Macular Degeneration. Current Drug Targets, 2011, 12, 173-181.	2.1	95
164	Extracellular matrix in angiogenesis: dynamic structures with translational potential. Experimental Dermatology, 2011, 20, 605-613.	2.9	55
165	Ranibizumab: a medical treatment that requires surgical administration. Eye, 2011, 25, 399-401.	2.1	7
166	Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab. Eye, 2011, 25, 661-672.	2.1	110
167	Validation of Molecular and Genomic Biomarkers of Retinal Drug Efficacy: Use of Ocular Fluid Sampling to Evaluate VEGF. Neurochemical Research, 2011, 36, 655-667.	3.3	3
168	VEGF-C differentially regulates VEGF-A expression in ocular and cancer cells; promotes angiogenesis via RhoA mediated pathway. Angiogenesis, 2011, 14, 371-380.	7.2	33
169	VEGF non-angiogenic functions in adult organ homeostasis: therapeutic implications. Journal of Molecular Medicine, 2011, 89, 635-645.	3.9	24
171	Total Chemical Synthesis of Biologically Active Vascular Endothelial Growth Factor. Angewandte Chemie - International Edition, 2011, 50, 8029-8033.	13.8	49
172	AltersabhÃ <b>¤</b> gige Makuladegeneration. , 2011, , .		3
173	Notch Signaling in Developmental and Tumor Angiogenesis. Genes and Cancer, 2011, 2, 1106-1116.	1.9	121
175	The Small GTPase Rap1 Is a Novel Regulator of RPE Cell Barrier Function. , 2011, 52, 7455.		30
176	Intravitreal Concentrations of a Near-Infrared Fluorescence–Labeled Biotherapeutic Determined In Situ Using Confocal Scanning Laser Ophthalmoscopy 2011 52 6949		3

	CITATION REPORT	
ARTICLE	IF	CITATIONS
Intravitreal Ranibizumab and Bevacizumab in Combination with Full-Fluence Verteporfin Therapy a Dexamethasone for Exudative Age-Related Macular Degeneration. Ophthalmic Research, 2011, 45 129-134.	ind , 1.9	20
Intravitreal Bevacizumab in Refractory Neovascular Glaucoma. JAMA Ophthalmology, 2011, 129, 1	.45. 2.4	34
Ranibizumab Treatment for Choroidal Neovascularization from Causes Other than Age-Related Macular Degeneration and Pathological Myopia. Ophthalmologica, 2011, 225, 81-88.	1.9	35
VEGF-PET Imaging Is a Noninvasive Biomarker Showing Differential Changes in the Tumor during Sunitinib Treatment. Cancer Research, 2011, 71, 143-153.	0.9	105
Systemic Adverse Drug Reactions Secondary to Anti-VEGF Intravitreal Injection in Patients with Neovascular Age-Related Macular Degeneration. Current Vascular Pharmacology, 2011, 9, 629-64	6. 1.7	39
Efficacy and safety of anti-vascular endothelial growth factor (VEGF) therapy with intravitreal ranibizumab (Lucentis) for naive retinal vein occlusion: 1-year follow-up. British Journal of Ophthalmology, 2011, 95, 56-68.	3.9	26
The Impact of Subconjuctivally Injected EGF and VEGF Inhibitors on Experimental Corneal Neovascularization in Rat Model. Current Eye Research, 2011, 36, 1005-1013.	1.5	38
Effectiveness of ranibizumab for neovascular age-related macular degeneration using clinician-determined retreatment strategy. British Journal of Ophthalmology, 2011, 95, 530-533.	3.9	34
Activation of the Alternative Complement Pathway in Vitreous is Controlled by Genetics in Age-Related Macular Degeneration. , 2012, 53, 6628.		68
Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study. BMJ, The, 2012, 345, e4203-e4203.	6.0	83
Actions of bevacizumab and ranibizumab on microvascular retinal endothelial cells: similarities and differences. British Journal of Ophthalmology, 2012, 96, 1023-1028.	J 3.9	34
Diabetic macular edema: Current and emerging therapies. Middle East African Journal of Ophthalmology, 2012, 19, 4.	0.3	38
Ranibizumab treatment of retinal vein occlusion. Expert Review of Ophthalmology, 2012, 7, 509-5		0
Clinical and Electrophysiologic Outcome in Patients with Neovascular Glaucoma Treated with and without Bevacizumab. European Journal of Ophthalmology, 2012, 22, 563-574.	1.3	28
PROSPECTIVE RANDOMIZED CONTROLLED TRIAL OF COMBINATION RANIBIZUMAB (LUCENTIS) A BROMFENAC (XIBROM) FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 20 417-423.	ND 112, 32, 1.7	35
INTRAVITREAL RANIBIZUMAB VERSUS BEVACIZUMAB FOR TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION. Retina, 2012, 32, 1539-1546.	1.7	73

193	New developments in the treatment of diabetic macular edema: latest clinical evidence. Clinical Investigation, 2012, 2, 89-105.	0.0	0
194	Biological, Preclinical and Clinical Characteristics of Inhibitors of Vascular Endothelial Growth Factors. Ophthalmologica, 2012, 227, 2-10.	1.9	40

#

177

179

181

183

184

185

187

189

190

191

#	Article	IF	CITATIONS
195	EXTEND III: Efficacy and safety of ranibizumab in South Korean and Taiwanese patients with subfoveal CNV secondary to AMD. Graefe's Archive for Clinical and Experimental Ophthalmology, 2012, 250, 1467-1476.	1.9	12
196	Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicines. Graefe's Archive for Clinical and Experimental Ophthalmology, 2012, 250, 1563-1571.	1.9	22
198	The Expanding Role of Vascular Endothelial Growth Factor Inhibitors in Ophthalmology. Mayo Clinic Proceedings, 2012, 87, 77-88.	3.0	162
199	Canadian expert consensus: optimal treatment of neovascular age-related macular degeneration. Canadian Journal of Ophthalmology, 2012, 47, 227-235.	0.7	22
200	Assessment of Differential Pharmacodynamic Effects Using Optical Coherence Tomography in Neovascular Age-Related Macular Degeneration. , 2012, 53, 1152.		20
201	The neurosteroid dehydroepiandrosterone (DHEA) protects the retina from AMPA-induced excitotoxicity: NGF TrkA receptor involvement. Neuropharmacology, 2012, 62, 2106-2117.	4.1	27
202	HORIZON: An Open-Label Extension Trial of Ranibizumab for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. Ophthalmology, 2012, 119, 1175-1183.	5.2	324
203	Ranibizumab for Diabetic Macular Edema. Ophthalmology, 2012, 119, 789-801.	5.2	1,392
204	Verteporfin plus Ranibizumab for Choroidal Neovascularization in Age-Related Macular Degeneration. Ophthalmology, 2012, 119, 1001-1010.	5.2	115
205	Subfoveal Choroidal Thickness after Ranibizumab Therapy for Neovascular Age-related Macular Degeneration: 12-Month Results. Ophthalmology, 2012, 119, 1621-1627.	5.2	152
206	Aflibercept for Age-Related Macular Degeneration: A Game-Changer or Quiet Addition?. American Journal of Ophthalmology, 2012, 154, 222-226.	3.3	128
207	Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. , 2012, 12, CD007419.		75
208	Ranibizumab. Drugs, 2012, 72, 509-523.	10.9	25
209	Intraocular Pharmacokinetics of Ranibizumab Following a Single Intravitreal Injection in Humans. American Journal of Ophthalmology, 2012, 154, 682-686.e2.	3.3	202
210	Uveitis, the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT), and Intravitreal Biologics for Ocular Inflammation. American Journal of Ophthalmology, 2012, 154, 429-435.e2.	3.3	15
211	Effects of bevacizumab on neuronal viability of retinal ganglion cells in rats. Brain Research, 2012, 1478, 55-63.	2.2	37
212	Effects of ranibizumab on very low birth weight infants with stage 3 retinopathy of prematurity: A preliminary report. Taiwan Journal of Ophthalmology, 2012, 2, 136-139.	0.7	8
213	Anti-Vascular Endothelial Growth Factor Treatment for Retinal Vein Occlusions. Ophthalmologica, 2012, 227, 30-35.	1.9	51

#	Article	IF	CITATIONS
214	Anti-VEGF therapy for the treatment of glaucoma: a focus on ranibizumab and bevacizumab. Expert Opinion on Biological Therapy, 2012, 12, 1641-1647.	3.1	27
215	Mechanisms of Pathological VEGF Production in the Retina and Modification with VEGF-Antagonists. , 2012, , 277-305.		8
216	Pharmakologische Basis der Anti-VEGF Therapie. Spektrum Der Augenheilkunde, 2012, 26, 185-196.	0.3	0
217	Comparison of Systemic Adverse Events Associated with Intravitreal Anti-VEGF Injection: Ranibizumab versus Bevacizumab. Journal of Korean Medical Science, 2012, 27, 1580.	2.5	19
218	Development of Anti-VEGF Therapies for Intraocular Use: A Guide for Clinicians. Journal of Ophthalmology, 2012, 2012, 1-13.	1.3	42
219	Treatment of Neovascular Age Related Macular Degeneration. , 2012, , .		0
220	Comparative study of 1+PRN ranibizumab versus bevacizumab in the clinical setting. Clinical Ophthalmology, 2012, 6, 1149.	1.8	21
221	Anti-VEGF Treatment Strategies for Wet AMD. Journal of Ophthalmology, 2012, 2012, 1-7.	1.3	149
222	Targeting Tumor Microenvironments for Cancer Prevention and Therapy. , 2012, , .		4
223	Choroidal thickness after intravitreal ranibizumab injections for choroidal neovascularization. Clinical Ophthalmology, 2012, 6, 837.	1.8	45
224	Profile of ranibizumab: efficacy and safety for the treatment of wet age-related macular degeneration. Therapeutics and Clinical Risk Management, 2012, 8, 343.	2.0	15
225	Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis, 2012, 15, 171-185.	7.2	838
226	Vascular endothelial growth factor plasma levels before and after treatment of neovascular ageâ€related macular degeneration with bevacizumab or ranibizumab. Acta Ophthalmologica, 2012, 90, e25-30.	1.1	134
227	Ranibizumab in South Korean and Taiwanese patients with ageâ€related macular degeneration: primary outcome of the EXTEND III study. Acta Ophthalmologica, 2012, 90, e406-7.	1.1	4
228	From oxygen to erythropoietin: Relevance of hypoxia for retinal development, health and disease. Progress in Retinal and Eye Research, 2012, 31, 89-119.	15.5	133
229	The impact of ageing on the barriers to drug delivery. Journal of Controlled Release, 2012, 161, 389-398.	9.9	42
230	The development of encapsulated cell technologies as therapies for neurological and sensory diseases. Journal of Controlled Release, 2012, 160, 3-13.	9.9	46
231	Stem cells: a new paradigm for disease modeling and developing therapies for age-related macular degeneration. Journal of Translational Medicine, 2013, 11, 53.	4.4	30

#	Article	IF	CITATIONS
232	Ranibizumab efficiently blocks migration but not proliferation induced by growth factor combinations including VEGF in retinal endothelial cells. Graefe's Archive for Clinical and Experimental Ophthalmology, 2013, 251, 2345-2353.	1.9	17
233	Ranibizumab: A Review of Its Use in the Treatment of Neovascular Age-Related Macular Degeneration. Drugs and Aging, 2013, 30, 331-358.	2.7	42
234	Aflibercept for the Treatment of Age-Related Macular Degeneration. Ophthalmology and Therapy, 2013, 2, 89-98.	2.3	26
235	Anti-VEGF Therapy for the Management of Diabetic Macular Edema. Current Ophthalmology Reports, 2013, 1, 122-127.	1.2	4
236	Treatment Paradigms in Neovascular AMD. Current Ophthalmology Reports, 2013, 1, 12-19.	1.2	0
237	Vascular Endothelial Growth Factor A in Intraocular Vascular Disease. Ophthalmology, 2013, 120, 106-114.	5.2	334
238	Treatment of Diabetic Macular Edema With a Designed Ankyrin Repeat Protein That Binds Vascular Endothelial Growth Factor: A Phase I/II Study. American Journal of Ophthalmology, 2013, 155, 697-704.e2.	3.3	102
239	Girdin and Its Phosphorylation Dynamically Regulate Neonatal Vascular Development and Pathological Neovascularization in the Retina. American Journal of Pathology, 2013, 182, 586-596.	3.8	23
240	VEGF but not PIGF disturbs the barrier of retinal endothelial cells. Experimental Eye Research, 2013, 115, 162-171.	2.6	53
241	Incidence and Management of Elevated Intraocular Pressure with Antivascular Endothelial Growth Factor Agents. Seminars in Ophthalmology, 2013, 28, 126-130.	1.6	25
242	Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. British Journal of Ophthalmology, 2013, 97, 454-459.	3.9	150
243	Influence of the Vitreomacular Interface onÂOutcomes of Ranibizumab Therapy inÂNeovascular Age-related Macular Degeneration. Ophthalmology, 2013, 120, 2620-2629.	5.2	74
244	Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III Trials. Ophthalmology, 2013, 120, 2013-2022.	5.2	728
245	Alginate-based strategies for therapeutic vascularization. Therapeutic Delivery, 2013, 4, 327-341.	2.2	33
246	Periplasmic expression optimization of VEGFR2 D3 adopting response surface methodology: Antiangiogenic activity study. Protein Expression and Purification, 2013, 90, 55-66.	1.3	14
247	Helical peptides from VEGF and Vammin hotspots for modulating the VEGF–VEGFR interaction. Organic and Biomolecular Chemistry, 2013, 11, 1896.	2.8	27
248	Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion. The Cochrane Library, 2013, , CD009510.	2.8	58
249	Ocular neovascularization. Journal of Molecular Medicine, 2013, 91, 311-321.	3.9	308

#	Article	IF	CITATIONS
250	Age-Related Macular Degeneration. Pharmacotherapy, 2013, 33, 838-855.	2.6	95
251	Aflibercept (VEGF Trap-Eye) for the treatment of exudative age-related macular degeneration. Expert Review of Clinical Pharmacology, 2013, 6, 103-113.	3.1	22
252	Two-Year Safety and Efficacy of Ranibizumab 0.5 mg in Diabetic Macular Edema. Ophthalmology, 2013, 120, 2004-2012.	5.2	112
253	The SECURE Study. Ophthalmology, 2013, 120, 130-139.	5.2	81
254	Retinal Functional Changes Measured by Microperimetry in Neovascular Age-Related Macular Degeneration Treated With Ranibizumab. American Journal of Ophthalmology, 2013, 155, 118-126.e1.	3.3	24
255	Short-term impact of intravitreal ranibizumab injection on axial ocular dimension and intraocular pressure. Cutaneous and Ocular Toxicology, 2013, 32, 23-26.	1.3	19
256	Anti-VEGF Therapy: Basics and Substances. , 2013, , 225-231.		2
257	Anti-VEGF Therapy for AMD: Results and Guidelines. , 2013, , 233-245.		1
258	Aflibercept ophthalmic solution: drug development and clinical uses. Clinical Investigation, 2013, 3, 1045-1056.	0.0	2
259	In vitro induction of protein complexes between bevacizumab, VEGF-A165and heparin: explanation for deposits observed on endothelial veins in monkey eyes. British Journal of Ophthalmology, 2013, 97, 511-517.	3.9	10
260	Anti-vascular endothelial growth factor drugs safety and efficacy in ophthalmic diseases. Journal of Pharmacology and Pharmacotherapeutics, 2013, 4, S38-S42.	0.4	37
261	Vitreous Inflammation Associated with Intravitreal Anti-VEGF Pharmacotherapy. Mediators of Inflammation, 2013, 2013, 1-6.	3.0	57
262	Pharmacokinetics of Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration: A Population Approach. , 2013, 54, 1616.		167
263	Anti-vascular endothelial growth factor therapy for diabetic macular edema. Therapeutic Advances in Endocrinology and Metabolism, 2013, 4, 151-169.	3.2	145
264	Phage Display for Protein Binding. , 2013, , 431-436.		1
265	Lessons learnt inform our approach to new antivascular endothelial growth factor treatments for neovascular ageâ€related macular degeneration. Clinical and Experimental Ophthalmology, 2013, 41, 723-726.	2.6	2
266	Intravitreal aflibercept use in the treatment of macular edema from central retinal vein occlusion. Expert Review of Ophthalmology, 2013, 8, 227-235.	0.6	1
268	INTRAVITREOUS RANIBIZUMAB FOR PERSISTENT MACULAR EDEMA IN RETINAL VEIN OCCLUSION UNRESPONSIVE TO BEVACIZUMAB. Retinal Cases and Brief Reports, 2013, 7, 220-224.	0.6	3

#	Article	IF	CITATIONS
269	RANIBIZUMAB FOR CHOROIDAL NEOVASCULARIZATION ASSOCIATED WITH ADULT-ONSET FOVEOMACULAR VITELLIFORM DYSTROPHY. Retina, 2013, 33, 513-521.	1.7	34
270	THE EFFECTS OF AFLIBERCEPT ON THE VIABILITY AND METABOLISM OF OCULAR CELLS IN VITRO. Retina, 2013, 33, 1056-1061.	1.7	24
271	The Effect of Bevacizumab versus Ranibizumab in the Treatment of Corneal Neovascularization: A Preliminary Study. Korean Journal of Ophthalmology: KJO, 2013, 27, 235.	1.1	18
272	Vascular endothelial growth factor inhibitors: investigational therapies for the treatment of psoriasis. Clinical, Cosmetic and Investigational Dermatology, 2013, 6, 233.	1.8	29
273	Risk Factors for Retinal Pigment Epithelium Tears after Anti-VEGF Agent Injection in Age-Related Macular Degeneration. Journal of Korean Ophthalmological Society, 2013, 54, 1546.	0.2	2
274	Assessing a Novel Depot Delivery Strategy for Noninvasive Administration of VEGF/PDGF RTK Inhibitors for Ocular Neovascular Disease. , 2013, 54, 1490.		49
275	Critical appraisal of ranibizumab in the treatment of diabetic macular edema. Clinical Ophthalmology, 2013, 7, 1257.	1.8	19
276	Combined Scraping, Coagulation, and Subconjunctival Bevacizumab in Descemet Stripping Automated Endothelial Keratoplasty for Bullous Keratopathy. European Journal of Ophthalmology, 2013, 23, 309-315.	1.3	1
278	Transcriptional Regulation of VEGFA by the Endoplasmic Reticulum Stress Transducer OASIS in ARPE-19 Cells. PLoS ONE, 2013, 8, e55155.	2.5	23
279	Single and multiple injections of subconjunctival ranibizumab for early, recurrent pterygium. Clinical Ophthalmology, 2013, 7, 467.	1.8	16
280	Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema. Clinical Interventions in Aging, 2013, 8, 467.	2.9	34
281	Long-Term Effect of Intravitreal Ranibizumab Injection on Choroidal Neovascularization in Age-Related Macular Degeneration. Journal of Korean Ophthalmological Society, 2013, 54, 1359.	0.2	5
282	Angiogenic Potential of Vitreous from Proliferative Diabetic Retinopathy and Eales' Disease Patients. PLoS ONE, 2014, 9, e107551.	2.5	37
283	Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration. Journal of Ophthalmology, 2014, 2014, 1-6.	1.3	14
284	Spectral-Domain Optical Coherence Tomography for Macular Edema. Scientific World Journal, The, 2014, 2014, 1-6.	2.1	10
285	Ranibizumab for the treatment of degenerative ocular conditions. Clinical Ophthalmology, 2014, 8, 1187.	1.8	17
286	Epimacular brachytherapy for wet AMD: current perspectives. Clinical Ophthalmology, 2014, 8, 1661.	1.8	7
287	Avaliação dos Resultados do Tratamento Antiangiogénico na Neovascularização Coroideia Associada à Miopia Patológica. Acta Medica Portuguesa, 2014, 27, 49.	0.4	1

#	Article	IF	CITATIONS
288	Development of an Experimental Model of Proliferative Retinopathy by Intravitreal Injection of VEGF165. Journal of Ocular Pharmacology and Therapeutics, 2014, 30, 752-756.	1.4	1
289	Endoglin Promotes Angiogenesis in Cell- and Animal-Based Models of Retinal Neovascularization. , 2014, 55, 6490.		28
290	Success of Ranibizumab in Central Serous Chorioretinopathy Resistant to Bevacizumab. Journal of Ocular Pharmacology and Therapeutics, 2014, 30, 842-846.	1.4	7
291	Reducing the clinical burden of ranibizumab treatment for neovascular age-related macular degeneration using an individually planned regimen. British Journal of Ophthalmology, 2014, 98, 1192-1196.	3.9	61
293	Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion. The Cochrane Library, 2014, 2014, CD007325.	2.8	83
294	Intraretinal cysts are the most relevant prognostic biomarker in neovascular age-related macular degeneration independent of the therapeutic strategy. British Journal of Ophthalmology, 2014, 98, 1629-1635.	3.9	67
295	Comparison of Acute Effect of Systemic Versus Intravitreal Infliximab Treatment in an Experimental Model of Endotoxin-Induced Uveitis. Journal of Ocular Pharmacology and Therapeutics, 2014, 30, 74-80.	1.4	10
296	Ranibizumab for age-related macular degeneration: a meta-analysis of dose effects and comparison with no anti-VEGF treatment and bevacizumab. Journal of Clinical Pharmacy and Therapeutics, 2014, 39, 234-239.	1.5	17
297	Cardiac Issues of Noncardiac Drugs: The Rising Story of Avastin in Age-Related Macular Degeneration. Ophthalmologica, 2014, 231, 75-79.	1.9	8
298	Gene profiling of human VEGF signaling pathways in human endothelial and retinal pigment epithelial cells after anti VEGF treatment. BMC Research Notes, 2014, 7, 617.	1.4	8
299	POOR RESPONDERS TO BEVACIZUMAB PHARMACOTHERAPY IN AGE-RELATED MACULAR DEGENERATION AND IN DIABETIC MACULAR EDEMA DEMONSTRATE INCREASED RISK FOR OBSTRUCTIVE SLEEP APNEA. Retina, 2014, 34, 2423-2430.	1.7	40
300	SUBFOVEAL CHOROIDAL THICKNESS CHANGE AFTER INTRAVITREAL RANIBIZUMAB FOR IDIOPATHIC CHOROIDAL NEOVASCULARIZATION. Retina, 2014, 34, 1554-1559.	1.7	11
301	Intracameral Ranibizumab and Subsequent Mitomycin C Augmented Trabeculectomy in Neovascular Glaucoma. Journal of Glaucoma, 2014, 23, 437-440.	1.6	19
302	Intravitreal Ranibizumab Injection for Idiopathic Choroidal Neovascularization in Children. Seminars in Ophthalmology, 2014, 29, 178-181.	1.6	6
303	Drugs for Macular Degeneration. JAMA - Journal of the American Medical Association, 2014, 312, 2044.	7.4	0
304	EXTEND II: An Open-Label Phase III Multicentre Study to Evaluate Efficacy and Safety of Ranibizumab in Chinese Patients with Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. BioDrugs, 2014, 28, 527-536.	4.6	10
305	Pharmacological Approach to Diabetic Macular Edema. Ophthalmic Research, 2014, 51, 88-95.	1.9	21
306	CLINICAL EVALUATION OF PAZOPANIB EYE DROPS IN HEALTHY SUBJECTS AND IN SUBJECTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION, Reting, 2014, 34, 1787-1795.	1.7	21

#	Article	IF	CITATIONS
307	Topical Ranibizumab inhibits inflammatory corneal hem―and lymphangiogenesis. Acta Ophthalmologica, 2014, 92, 143-148.	1.1	33
308	RADIANCE: A Randomized Controlled Study of Ranibizumab in Patients with Choroidal Neovascularization Secondary to Pathologic Myopia. Ophthalmology, 2014, 121, 682-692.e2.	5.2	274
309	Anti-vascular endothelial growth factor for diabetic macular oedema. , 2014, , CD007419.		113
310	Complications of Subspecialty Ophthalmic Care: Systemic Complications from the Intravitreal Administration of Agents that Target the Vascular Endothelial Growth Factor Pathway. Seminars in Ophthalmology, 2014, 29, 263-275.	1.6	9
311	Pharmacokinetics of Ranibizumab after Intravitreal Administration in Patients with Retinal Vein Occlusion or Diabetic Macular Edema. Ophthalmology, 2014, 121, 2237-2246.	5.2	29
312	Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGF. Expert Review of Clinical Pharmacology, 2014, 7, 167-180.	3.1	75
313	Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. , 2014, , CD011230.		106
314	Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. British Journal of Ophthalmology, 2014, 98, 1636-1641.	3.9	302
315	Twenty-four-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration. Ophthalmology, 2014, 121, 2181-2192.	5.2	377
316	Monthly Versus As-Needed Ranibizumab Injections in Patients with Retinal Vein Occlusion. Ophthalmology, 2014, 121, 2432-2442.	5.2	71
317	Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes. British Journal of Ophthalmology, 2014, 98, 813-825.	3.9	112
318	Anti-VEGF Therapy for Diabetic Macular Edema. Current Diabetes Reports, 2014, 14, 510.	4.2	60
319	Comparison of 1-year therapeutic effect of ranibizumab and bevacizumab for myopic choroidal neovascularization: a retrospective, multicenter, comparative study. BMC Ophthalmology, 2014, 14, 69.	1.4	18
320	Comparison of Binding Characteristics and In Vitro Activities of Three Inhibitors of Vascular Endothelial Growth Factor A. Molecular Pharmaceutics, 2014, 11, 3421-3430.	4.6	73
321	Three-Year Outcomes of Individualized Ranibizumab Treatment in Patients with Diabetic Macular Edema. Ophthalmology, 2014, 121, 1045-1053.	5.2	347
322	Intraocular Pressure in Eyes Receiving Monthly Ranibizumab in 2 Pivotal Age-Related Macular Degeneration Clinical Trials. Ophthalmology, 2014, 121, 1102-1108.	5.2	84
323	VEGFA Activates Erythropoietin Receptor and Enhances VEGFR2-Mediated Pathological Angiogenesis. American Journal of Pathology, 2014, 184, 1230-1239.	3.8	59
324	Capacity of aflibercept to counteract VEGF-stimulated abnormal behavior of retinal microvascular endothelial cells. Experimental Eye Research, 2014, 122, 20-31.	2.6	40

#	Article	IF	CITATIONS
325	Safety and Efficacy of Conbercept in Neovascular Age-Related Macular Degeneration. Ophthalmology, 2014, 121, 1740-1747.	5.2	148
326	Impact of Vitreomacular Adhesion on Ranibizumab Mono- and Combination Therapy for Neovascular Age-Related Macular Degeneration. American Journal of Ophthalmology, 2014, 158, 328-336.e1.	3.3	35
327	Morphologic Parameters Relevant for Visual Outcome During Anti-Angiogenic Therapy of Neovascular Age-Related Macular Degeneration. Ophthalmology, 2014, 121, 1237-1245.	5.2	146
328	Interleukinâ€18 Has Antipermeablity and Antiangiogenic Activities in the Eye: Reciprocal Suppression With VEGF. Journal of Cellular Physiology, 2014, 229, 974-983.	4.1	39
330	Therapeutic Monoclonal Antibodies and Fragments: Ranibizumab. Developments in Ophthalmology, 2016, 55, 246-251.	0.1	7
332	Therapeutic effect of intravitreal injections of ranibizumab for the treatment of macular choroidal neovascularization caused by pathological myopia. Experimental and Therapeutic Medicine, 2015, 10, 1121-1126.	1.8	2
333	Angiogenesis and Eye Disease. Annual Review of Vision Science, 2015, 1, 155-184.	4.4	41
334	Bevacizumab and Aflibercept Activate Platelets via FcγRIIa. , 2015, 56, 8075.		17
335	Systemic Counterregulatory Response of Placental Growth Factor Levels to Intravitreal Aflibercept Therapy. , 2015, 56, 3279.		17
336	Design and Pharmacokinetic Characterization of Novel Antibody Formats for Ocular Therapeutics. , 2015, 56, 5390.		58
337	Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration Resistant to Bevacizumab and Ranibizumab. Journal of Korean Ophthalmological Society, 2015, 56, 1359.	0.2	10
338	Pharmakologische Ans̾ze zur Behandlung des diabetischen Makula̦dems. Karger Kompass Ophthalmologie, 2015, 1, 8-15.	0.0	0
339	Effects of Vitreomacular Traction on Ranibizumab Treatment Response in Eyes with Neovascular Age-related Macular Degeneration. Korean Journal of Ophthalmology: KJO, 2015, 29, 396.	1.1	5
340	Profile of conbercept in the treatment of neovascular age-related macular degeneration. Drug Design, Development and Therapy, 2015, 9, 2311.	4.3	66
341	Gene Therapy with Endogenous Inhibitors of Angiogenesis for Neovascular Age-Related Macular Degeneration: Beyond Anti-VEGF Therapy. Journal of Ophthalmology, 2015, 2015, 1-12.	1.3	16
342	Ranibizumab for Visual Impairment due to Diabetic Macular Edema: Real-World Evidence in the Italian Population (PRIDE Study). Journal of Ophthalmology, 2015, 2015, 1-10.	1.3	17
343	Influence of Glycosylated Hemoglobin on the Efficacy of Ranibizumab for Diabetic Macular Edema. Ophthalmology, 2015, 122, 1573-1579.	5.2	50
344	The REVEAL Study. Ophthalmology, 2015, 122, 1402-1415.	5.2	149

#	Article	IF	CITATIONS
345	Clinical Evaluation of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections in Subjects with Neovascular Age-Related Macular Degeneration. Ophthalmology, 2015, 122, 579-588.	5.2	57
346	Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with ageâ€related macular degeneration: a randomised, prospective trial. Acta Ophthalmologica, 2015, 93, e154-9.	1.1	76
347	Targeted localized use of therapeutic antibodies: a review of non-systemic, topical and oral applications. Critical Reviews in Biotechnology, 2015, 36, 1-15.	9.0	28
348	Therapies for Macular Edema Associated withÂCentral Retinal Vein Occlusion. Ophthalmology, 2015, 122, 769-778.	5.2	75
349	Genetic predictive biomarkers of anti-VEGF treatment response in patients with neovascular age-related macular degeneration. Survey of Ophthalmology, 2015, 60, 138-152.	4.0	31
350	Short-Term Changes in Choroidal Thickness After Aflibercept Therapy for Neovascular Age-Related Macular Degeneration. American Journal of Ophthalmology, 2015, 159, 627-633.e1.	3.3	91
351	Antibody therapies and their challenges in the treatment of age-related macular degeneration. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 95, 158-172.	4.3	54
352	Intravitreal dexamethasone implant versus anti-VEGF injection for treatment-naÃ <sup>-</sup> ve patients with retinal vein occlusion and macular edema: a 12-month follow-up study. Graefe's Archive for Clinical and Experimental Ophthalmology, 2015, 253, 2095-2102.	1.9	20
353	Binding of VEGF-A is sufficient to abrogate the disturbing effects of VEGF-B together with VEGF-A on retinal endothelial cells. Graefe's Archive for Clinical and Experimental Ophthalmology, 2015, 253, 885-894.	1.9	3
354	Residual edema evaluation with ranibizumab 0.5 mg and 2.0 mg formulations for diabetic macular edem (REEF study). Eye, 2015, 29, 534-541.	<sup>la</sup> 2.1	32
355	The role of ranibizumab in the management of diabetic retinopathy. Expert Review of Ophthalmology, 2015, 10, 329-340.	0.6	1
356	Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment. Ophthalmology, 2015, 122, 1811-1819.	5.2	41
357	Storage stability of bevacizumab in polycarbonate and polypropylene syringes. Eye, 2015, 29, 820-827.	2.1	31
358	Functional Characterization of AAV-Expressed Recombinant Anti-VEGF Single-Chain Variable Fragmentsin Vitro. Journal of Ocular Pharmacology and Therapeutics, 2015, 31, 269-276.	1.4	5
359	Correlation between serum level of vascular endothelial growth factor and subfoveal choroidal thickness in patients with POEMS syndrome. Graefe's Archive for Clinical and Experimental Ophthalmology, 2015, 253, 1641-1646.	1.9	14
360	Ranibizumab for macular edema secondary to retinal vein occlusion: a meta-analysis of dose effects and comparison with no anti-VEGF treatment. BMC Ophthalmology, 2015, 15, 31.	1.4	17
361	Intravitreal Ranibizumab versus Isovolemic Hemodilution in the Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion: Twelve-Month Results of a Prospective, Randomized, Multicenter Trial. Ophthalmologica, 2015, 233, 8-17.	1.9	6
362	Aptamer Nanomedicine for Cancer Therapeutics: Barriers and Potential for Translation. ACS Nano, 2015, 9, 2235-2254.	14.6	228

		CITATION REP	ORT	
#	Article		IF	CITATIONS
363	Brachytherapy in Neovascular AMD. Current Ophthalmology Reports, 2015, 3, 40-50.		1.2	0
364	Prospective Comparison of Low-Fluence Photodynamic Therapy Combined with Intravi Bevacizumab versus Bevacizumab Monotherapy for Choroidal Neovascularization in Ag Macular Degeneration. Seminars in Ophthalmology, 2015, 30, 112-117.	treal ge-Related	1.6	10
365	Inhibition of Ocular Neovascularization by Co-Inhibition of VEGF-A and PLGF. Cellular P Biochemistry, 2015, 35, 1787-1796.	hysiology and	1.6	37
367	Intravitreal steroid and anti-vascular endothelial growth agents for the management of occlusion: evidence from randomized trials. Expert Opinion on Biological Therapy, 201	retinal vein 5, 15, 1685-1697.	3.1	16
368	Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related degeneration: a trade-off analysis. British Journal of Ophthalmology, 2015, 99, 141-146	1 macular 5.	3.9	87
369	Serum D-Dimer Levels to Evaluate the Risk for Arterial Thromboembolism After Intravit of Bevacizumab and Ranibizumab. Journal of Ocular Pharmacology and Therapeutics, 2	real Injection 015, 31, 32-36.	1.4	5
370	Drugs in Phase II clinical trials for the treatment of age-related macular degeneration. E on Investigational Drugs, 2015, 24, 183-199.	xpert Opinion	4.1	47
371	Correlation of Vascular Endothelial Growth Factor Production with Photochemical Reaction-induced Retinal Edema. Chinese Medical Journal, 2016, 129, 2944-2950.		2.3	4
373	VEGF and Intraocular Neovascularization: From Discovery to Therapy. Translational Visi and Technology, 2016, 5, 10.	on Science	2.2	74
374	Selection Strategy of In Vivo Models for Ophthalmic Drug Development in Diabetic Ret Journal of Molecular and Genetic Medicine: an International Journal of Biomedical Rese	inopathy. arch, 2016, 10, .	0.1	0
375	Topical Squalamine 0.2% and Intravitreal Ranibizumab 0.5 mg as Combination Therapy Edema Due to Branch and Central Retinal Vein Occlusion: An Open-Label, Randomized Ophthalmic Surgery Lasers and Imaging Retina, 2016, 47, 914-923.	for Macular Study.	0.7	20
376	Endogenous and Synthetic Cannabinoids as Therapeutics in Retinal Disease. Neural Pla 2016, 1-12.	sticity, 2016,	2.2	21
377	Designer Leptin Receptor Antagonist Allo-aca Inhibits VEGF Effects in Ophthalmic Neoa Models. Frontiers in Molecular Biosciences, 2016, 3, 67.	angiogenesis	3.5	6
378	Molecular Selection, Modification and Development of Therapeutic Oligonucleotide Ap International Journal of Molecular Sciences, 2016, 17, 358.	otamers.	4.1	50
379	Editor's Highlight: Subvisible Aggregates of Immunogenic Proteins Promote a Th1- Toxicological Sciences, 2016, 153, 258-270.	Type Response.	3.1	33
380	Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does n formation of immune-like complexes. Angiogenesis, 2016, 19, 389-406.	ot support	7.2	29
381	Systemic safety of intravitreal anti-vascular endothelial growth factor agents in age-rel degeneration. Current Opinion in Ophthalmology, 2016, 27, 224-243.	ated macular	2.9	14
382	Response to Anti-VEGF-A Treatment of Retinal Pigment Epithelial Cells In Vitro. Europe Ophthalmology, 2016, 26, 425-430.	an Journal of	1.3	9

#	Article	IF	CITATIONS
383	Ranibizumab in Myopic Choroidal Neovascularization: A Subgroup Analysis by Ethnicity, Age, and Ocular Characteristics in RADIANCE. Ophthalmologica, 2016, 236, 19-28.	1.9	20
384	Ocular microparticle formulations for 6-month delivery of anti-VEGF. Journal of Controlled Release, 2016, 244, 136.	9.9	2
386	Neuronal Differentiation of Induced Pluripotent Stem Cells on Surfactant Templated Chitosan Hydrogels. Biomacromolecules, 2016, 17, 1684-1695.	5.4	38
387	Clinical Efficacy and Safety of Ranibizumab Versus Dexamethasone for Central Retinal Vein Occlusion (COMRADE C): A European Label Study. American Journal of Ophthalmology, 2016, 169, 258-267.	3.3	66
388	Internalization of bevacizumab by retinal endothelial cells and its intracellular fate: Evidence for an involvement of the neonatal Fc receptor. Experimental Eye Research, 2016, 143, 49-59.	2.6	18
389	Drug, delivery and devices for diabetic retinopathy (3Ds in DR). Expert Opinion on Drug Delivery, 2016, 13, 1625-1637.	5.0	13
390	Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration. Ophthalmology, 2016, 123, 617-624.	5.2	106
391	Is There Any Difference between Ranibizumab and Aflibercept Injections in Terms of Inflammation Measured with Anterior Chamber Flare Levels in Age-Related Macular Degeneration Patients: A Comparative Study. Ophthalmic Research, 2016, 56, 35-40.	1.9	8
393	Quantification of the vascular endothelial growth factor with a bioluminescence resonance energy transfer (BRET) based single molecule biosensor. Biosensors and Bioelectronics, 2016, 86, 609-615.	10.1	17
394	Short-Term Outcomes of Switching to Ranibizumab Therapy for Diabetic Macular Edema in Patients with Persistent Fluid After Bevacizumab Therapy. Journal of Ocular Pharmacology and Therapeutics, 2016, 32, 659-664.	1.4	14
395	A SEMA3E mutant resistant to cleavage by furins (UNCL-SEMA3E) inhibits choroidal neovascularization. Experimental Eye Research, 2016, 153, 186-194.	2.6	6
396	Site-Specific Photolabeling of the IgG Fab Fragment Using a Small Protein G Derived Domain. Bioconjugate Chemistry, 2016, 27, 2095-2102.	3.6	18
397	Commentary on "Humanization of an Anti-VEGF Monoclonal Antibody for the Therapy of Solid Tumors and Other Disordersâ€: Cancer Research, 2016, 76, 4913-4915.	0.9	3
398	Effects of intravitreally injected Fc fragment on rat eyes. Graefe's Archive for Clinical and Experimental Ophthalmology, 2016, 254, 2401-2409.	1.9	3
399	Anti-angiogenic Therapy for Retinal Disease. Handbook of Experimental Pharmacology, 2016, 242, 271-307.	1.8	38
400	Involvement of B cells in nonâ€infectious uveitis. Clinical and Translational Immunology, 2016, 5, e63.	3.8	51
401	TREAT-AND-EXTEND REGIMEN WITH AFLIBERCEPT FOR RETINAL ANGIOMATOUS PROLIFERATION. Retina, 2016, 36, 2282-2289.	1.7	33
402	Comparison of intravitreal aflibercept and ranibizumab injections on subfoveal and peripapillary choroidal thickness in eyes with neovascular age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology, 2016, 254, 1693-1702.	1.9	32

#	Article	IF	CITATIONS
403	Counterfeit Avastin in India: Punish the Criminals, Not the Patients. American Journal of Ophthalmology, 2016, 170, 228-231.	3.3	26
404	Choroidal Thickness Changes After Intravitreal Ranibizumab for Exudative Age-Related Macular Degeneration. BioDrugs, 2016, 30, 353-359.	4.6	8
405	PLGA Microparticles Entrapping Chitosan-Based Nanoparticles for the Ocular Delivery of Ranibizumab. Molecular Pharmaceutics, 2016, 13, 2923-2940.	4.6	92
406	Extended duration strategies for the pharmacologic treatment of diabetic retinopathy: current status and future prospects. Expert Opinion on Drug Delivery, 2016, 13, 1277-1287.	5.0	21
407	Ranibizumab. Journal of Pharmacy Technology, 2016, 32, 22-28.	1.0	4
408	Response to anti-VEGF-A treatment of endothelial cells inÂvitro. Experimental Eye Research, 2016, 146, 128-136.	2.6	10
409	A Mechanistic Model of the Intravitreal Pharmacokinetics of Large Molecules and the Pharmacodynamic Suppression of Ocular Vascular Endothelial Growth Factor Levels by Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration. Molecular Pharmaceutics, 2016, 13, 2941-2950.	4.6	65
410	Ten years of anti-vascular endothelial growth factor therapy. Nature Reviews Drug Discovery, 2016, 15, 385-403.	46.4	724
411	Effects of Intravitreal Ranibizumab in the Treatment of Retinopathy of Prematurity in Chinese Infants. Current Eye Research, 2016, 41, 1092-1097.	1.5	21
412	Intravitreal anti-vascular endothelial growth factor combined with half-fluence photodynamic therapy for choroidal neovascularization in chronic central serous chorioretinopathy. Eye, 2016, 30, 805-811.	2.1	29
413	Central retinal vein occlusion: modifying current treatment protocols. Eye, 2016, 30, 505-514.	2.1	33
414	Fit for the Eye: Aptamers in Ocular Disorders. Nucleic Acid Therapeutics, 2016, 26, 127-146.	3.6	103
415	Retinal Vein Occlusions: Therapeutic Switch in Macular Oedema Treatment with a 12-Month Follow-Up. Ophthalmic Research, 2016, 55, 152-158.	1.9	14
416	Role of VEGF Inhibition in the Treatment of Retinopathy of Prematurity. Seminars in Ophthalmology, 2016, 31, 163-168.	1.6	26
417	Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy. Expert Opinion on Biological Therapy, 2016, 16, 365-374.	3.1	74
418	Functional Deficits Precede Structural Lesions in Mice With High-Fat Diet–Induced Diabetic Retinopathy. Diabetes, 2016, 65, 1072-1084.	0.6	71
419	Risk of Myocardial Infarction and Stroke With Single or Repeated Doses of Intravitreal Bevacizumab in Age-Related Macular Degeneration. American Journal of Ophthalmology, 2016, 163, 53-58.	3.3	19
420	Safety of monoclonal antibodies and related therapeutic proteins for the treatment of neovascular macular degeneration: addressing outstanding issues. Expert Opinion on Drug Safety, 2016, 15, 75-87.	2.4	8

#	Article	IF	CITATIONS
421	Aflibercept: A Review of Its Use in the Management of Diabetic Eye Complications. Journal of Pharmacy Practice, 2017, 30, 534-540.	1.0	2
422	Evidence-Based Treatment of Diabetic Macular Edema. Seminars in Ophthalmology, 2017, 32, 56-66.	1.6	20
423	Considerations for management of patients with diabetic macular edema: Optimizing treatment outcomes and minimizing safety concerns through interdisciplinary collaboration. Diabetes Research and Clinical Practice, 2017, 126, 1-9.	2.8	7
424	Intravitreal Dexamethasone Implant versus Intravitreal Ranibizumab for the Treatment of Macular Edema Secondary to Retinal Vein Occlusion in a Chinese Population. Ophthalmic Research, 2017, 58, 8-14.	1.9	12
425	Ranibizumab Injection as Primary Treatment in Patients with Retinopathy of Prematurity. Ophthalmology, 2017, 124, 1156-1164.	5.2	62
426	Association between VEGF-A and VEGFR-2 polymorphisms and response to treatment of neovascular AMD with anti-VEGF agents: a meta-analysis. British Journal of Ophthalmology, 2017, 101, 976-984.	3.9	25
427	Targeting Vascular Endothelial Growth Factor. , 2017, , 99-139.		0
428	Developments in therapy with monoclonal antibodies and related proteins. Clinical Medicine, 2017, 17, 220-232.	1.9	137
429	Therapies for Macular Edema Associated with Branch Retinal Vein Occlusion. Ophthalmology, 2017, 124, 1412-1423.	5.2	57
430	Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab,) Tj ETQq1 1 0.784	314 rgBT	Overlock 10 28
	Opinialinology, 2017, 51, 99-105.	0.5	
431	A Review of Ranibizumab for the Treatment of Diabetic Retinopathy. Ophthalmology and Therapy, 2017, 6, 33-47.	2.3	31
431 434	A Review of Ranibizumab for the Treatment of Diabetic Retinopathy. Ophthalmology and Therapy, 2017, 6, 33-47. SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB. Retina, 2017, 37, 1847-1858.	2.3	<b>31</b> 234
431 434 435	A Review of Ranibizumab for the Treatment of Diabetic Retinopathy. Ophthalmology and Therapy, 2017, 6, 33-47. SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB. Retina, 2017, 37, 1847-1858. Anterior segment changes on ultrasound biomicroscopy after intravitreal anti vascular endothelial growth factor injection. Medical Journal Armed Forces India, 2017, 73, 58-64.	2.3 1.7 0.8	31 234 7
431 434 435 436	A Review of Ranibizumab for the Treatment of Diabetic Retinopathy. Ophthalmology and Therapy, 2017, 6, 33-47. SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB. Retina, 2017, 37, 1847-1858. Anterior segment changes on ultrasound biomicroscopy after intravitreal anti vascular endothelial growth factor injection. Medical Journal Armed Forces India, 2017, 73, 58-64. High-density lipoprotein mutant eye drops for the treatment of posterior eye diseases. Journal of Controlled Release, 2017, 266, 301-309.	0.3 2.3 1.7 0.8 9.9	31 234 7 34
<ul> <li>431</li> <li>434</li> <li>435</li> <li>436</li> <li>437</li> </ul>	A Review of Ranibizumab for the Treatment of Diabetic Retinopathy. Ophthalmology and Therapy, 2017, 6, 33-47. SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB. Retina, 2017, 37, 1847-1858. Anterior segment changes on ultrasound biomicroscopy after intravitreal anti vascular endothelial growth factor injection. Medical Journal Armed Forces India, 2017, 73, 58-64. High-density lipoprotein mutant eye drops for the treatment of posterior eye diseases. Journal of Controlled Release, 2017, 266, 301-309. Prevalence of Age-Related Macular Degeneration in Australia. JAMA Ophthalmology, 2017, 135, 1242.	<ul> <li>0.3</li> <li>2.3</li> <li>1.7</li> <li>0.8</li> <li>9.9</li> <li>2.5</li> </ul>	31 234 7 34 34
<ul> <li>431</li> <li>434</li> <li>435</li> <li>436</li> <li>437</li> <li>438</li> </ul>	A Review of Ranibizumab for the Treatment of Diabetic Retinopathy. Ophthalmology and Therapy, 2017, 6, 33-47. SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB. Retina, 2017, 37, 1847-1858. Anterior segment changes on ultrasound biomicroscopy after intravitreal anti vascular endothelial growth factor injection. Medical Journal Armed Forces India, 2017, 73, 58-64. High-density lipoprotein mutant eye drops for the treatment of posterior eye diseases. Journal of Controlled Release, 2017, 266, 301-309. Prevalence of Age-Related Macular Degeneration in Australia. JAMA Ophthalmology, 2017, 135, 1242. Cell Therapy for Ophthalmic Diseases. Molecular and Translational Medicine, 2017, , 249-279.	<ul> <li>2.3</li> <li>1.7</li> <li>0.8</li> <li>9.9</li> <li>2.5</li> <li>0.4</li> </ul>	31 234 7 34 34
<ul> <li>431</li> <li>434</li> <li>435</li> <li>436</li> <li>437</li> <li>438</li> <li>439</li> </ul>	A Review of Ranibizumab for the Treatment of Diabetic Retinopathy. Ophthalmology and Therapy, 2017, 6, 33-47. SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB. Retina, 2017, 37, 1847-1858. Anterior segment changes on ultrasound biomicroscopy after intravitreal anti vascular endothelial growth factor injection. Medical Journal Armed Forces India, 2017, 73, 58-64. High-density lipoprotein mutant eye drops for the treatment of posterior eye diseases. Journal of Controlled Release, 2017, 266, 301-309. Prevalence of Age-Related Macular Degeneration in Australia. JAMA Ophthalmology, 2017, 135, 1242. Cell Therapy for Ophthalmic Diseases. Molecular and Translational Medicine, 2017, , 249-279. 3D endothelial cell spheroid/human vitreous humor assay for the characterization of anti-angiogenic inhibitors for the treatment of proliferative diabetic retinopathy. Angiogenesis, 2017, 20, 629-640.	<ul> <li>2.3</li> <li>1.7</li> <li>0.8</li> <li>9.9</li> <li>2.5</li> <li>0.4</li> <li>7.2</li> </ul>	<ul> <li>31</li> <li>234</li> <li>7</li> <li>34</li> <li>34</li> <li>1</li> <li>16</li> </ul>

#	Article	IF	CITATIONS
441	NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH ADVANCED VISUAL LOSS TREATED WITH ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. Retina, 2017, 37, 257-264.	1.7	5
442	Inhibition of Single Routes of Intracellular Signaling is Not Sufficient to Neutralize the Biphasic Disturbance of a Retinal Endothelial Cell Barrier Induced by VEGF-A165. Cellular Physiology and Biochemistry, 2017, 42, 1493-1513.	1.6	12
443	Myopic Choroidal Neovascularization. Ophthalmology, 2017, 124, 1690-1711.	5.2	263
444	Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy. Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255, 1891-1897.	1.9	58
445	Effect of intravitreal ranibizumab injection on aqueous humour cytokine levels in patients with diabetic macular oedema. Acta Ophthalmologica, 2017, 95, e340-e341.	1.1	8
446	Pretreatment of RPE Cells with Lutein Can Mitigate Bevacizumab-Induced Increases in Angiogenin and bFGF. Ophthalmic Research, 2017, 57, 48-53.	1.9	7
447	A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration. International Ophthalmology, 2017, 37, 1205-1214.	1.4	27
448	Antiangiogenic effect of betaine on pathologic retinal neovascularization via suppression of reactive oxygen species mediated vascular endothelial growth factor signaling. Vascular Pharmacology, 2017, 90, 19-26.	2.1	17
449	Comparison of two individualized treatment regimens with ranibizumab for diabetic macular edema. Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255, 549-555.	1.9	15
450	Neonatal Fc receptor FcRn is involved in intracellular transport of the Fc fusion protein aflibercept and its transition through retinal endothelial cells. Experimental Eye Research, 2017, 154, 39-46.	2.6	11
451	Intravitreal ranibizumab for diabetic macular oedema in previously vitrectomized eyes. Acta Ophthalmologica, 2017, 95, 28-32.	1.1	26
452	Change in choroidal thickness after intravitreal injection for treatment of neovascular age-related macular degeneration: Ranibizumab versus aflibercept. Journal Francais D'Ophtalmologie, 2017, 40, 832-838.	0.4	13
453	The effect of intravitreal injections on dry eye, and proposed management strategies. Clinical Ophthalmology, 2017, Volume 11, 1491-1497.	1.8	13
454	Homocysteine Facilitates Prominent Polygonal Angiogenetic Networks of a Choroidal Capillary Sprouting Model. , 2017, 58, 4332.		2
455	The Impact of Switching Anti-Vascular Endothelial Growth Factor Therapy in the Management of Exudative Age-Related Macular Degeneration. Ophthalmic Surgery Lasers and Imaging Retina, 2017, 48, 859-869.	0.7	2
456	Response of eyes with age-related macular degeneration to anti-VEGF drugs and implications for therapy planning. Clinical Ophthalmology, 2017, Volume 11, 809-816.	1.8	10
457	Comparison of 12-month therapeutic effect of conbercept and ranibizumab for diabetic macular edema: a real-life clinical practice study. BMC Ophthalmology, 2017, 17, 158.	1.4	38
458	Changes in Retinal Microcirculation After Intravitreal Ranibizumab Injection in Eyes With Macular Edema Secondary to Branch Retinal Vein Occlusion. , 2017, 58, 1246.		28

#	Article	IF	CITATIONS
459	Switching between ranibizumab and aflibercept for the treatment of neovascular age-related macular degeneration. Survey of Ophthalmology, 2018, 63, 638-645.	4.0	41
460	The study of intravitreal drug pharmacokinetics: does it matter? and if so, how?. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 5-7.	3.3	7
461	The role of autophagy in ageâ€related macular degeneration. Acta Ophthalmologica, 2018, 96, 1-50.	1.1	10
462	Efficacy of treat-and-extend regimen with aflibercept for pachychoroid neovasculopathy and Type 1 neovascular age-related macular degeneration. Japanese Journal of Ophthalmology, 2018, 62, 144-150.	1.9	57
463	Efficacy and Safety of Ranibizumab 0.5 mg for the Treatment of Macular Edema Resulting from Uncommon Causes. Ophthalmology, 2018, 125, 850-862.	5.2	25
464	Long-term Progression of Type 1 Neovascularization in Age-related Macular Degeneration Using Optical Coherence Tomography Angiography. American Journal of Ophthalmology, 2018, 187, 10-20.	3.3	87
465	Treat-and-Extend Regimen with Aflibercept for Neovascular Age-Related Macular Degeneration. Ophthalmology Retina, 2018, 2, 462-468.	2.4	26
466	Development of Age-Related Macular Degeneration (AMD) in the Fellow Eye of Patients with AMD Treated by Treat-and-Extend Intravitreal Therapy with Aflibercept. Ophthalmologica, 2018, 239, 121-127.	1.9	2
467	Enhanced expression of soluble antibody fragments by low-temperature and overdosing with a nitrogen source. Enzyme and Microbial Technology, 2018, 115, 9-15.	3.2	9
468	Treatment outcomes of conventional or high-dose ranibizumab for vascularized pigment epithelial detachment based on lesion subtypes. European Journal of Ophthalmology, 2018, 28, 677-683.	1.3	2
469	Headâ€ŧoâ€head comparison of ranibizumab PRN versus singleâ€dose dexamethasone for branch retinal vein occlusion (COMRADEâ€B). Acta Ophthalmologica, 2018, 96, e10-e18.	1.1	48
470	In vitro-engineered non-antibody protein therapeutics. Protein and Cell, 2018, 9, 3-14.	11.0	134
471	VEGF-A gene polymorphisms and responses to intravitreal ranibizumab treatment in patients with diabetic macular edema. International Ophthalmology, 2018, 38, 2381-2388.	1.4	8
472	Analyzing Relative Blood Flow Speeds in Choroidal Neovascularization Using Variable Interscan Time Analysis OCT Angiography. Ophthalmology Retina, 2018, 2, 306-319.	2.4	19
473	Management of diabetic macular edema in Japan: a review and expert opinion. Japanese Journal of Ophthalmology, 2018, 62, 1-23.	1.9	44
474	Impact of Cataract Surgery during Treatment with Ranibizumab in Patients with Diabetic Macular Edema. Ophthalmology Retina, 2018, 2, 86-90.	2.4	13
475	EFFICACY AND SAFETY OF RANIBIZUMAB FOR THE TREATMENT OF CHOROIDAL NEOVASCULARIZATION DUE TO UNCOMMON CAUSE. Retina, 2018, 38, 1464-1477.	1.7	99
476	Hyperhomocysteinemia Causes Chorioretinal Angiogenesis with Placental Growth Factor Upregulation. Scientific Reports, 2018, 8, 15755.	3.3	7

#	Article	IF	CITATIONS
477	Anti-vascular Endothelial Growth Factor Treatment of Retinopathy of Prematurity: Efficacy, Safety, and Anatomical Outcomes. Korean Journal of Ophthalmology: KJO, 2018, 32, 451.	1.1	23
478	Flare levels after intravitreal injection of ranibizumab, aflibercept, or triamcinolone acetonide for diabetic macular edema. Graefe's Archive for Clinical and Experimental Ophthalmology, 2018, 256, 2301-2307.	1.9	11
479	Three-Dimensional Transport Model for Intravitreal and Suprachoroidal Drug Injection. , 2018, 59, 5266.		25
480	Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to ranibizumab treatment. Clinical Ophthalmology, 2018, Volume 12, 1877-1885.	1.8	23
481	One-step solid-oil-water emulsion for sustained bioactive ranibizumab release. Expert Opinion on Drug Delivery, 2018, 15, 1143-1156.	5.0	5
482	Two-year outcome of treat-and-extend aflibercept after ranibizumab in age-related macular degeneration and polypoidal choroidal vasculopathy patients. Clinical Ophthalmology, 2018, Volume 12, 1589-1597.	1.8	7
483	Repurposing antimalarial aminoquinolines and related compounds for treatment of retinal neovascularization. PLoS ONE, 2018, 13, e0202436.	2.5	11
484	Anti-vascular endothelial growth factor treatment for retinopathy of prematurity. Annals of Eye Science, 0, 2, 47-47.	2.1	3
485	Optical Coherence Tomography Angiography to Quantify Choroidal Neovascularization in Response to Aflibercept. Ophthalmologica, 2018, 240, 90-98.	1.9	21
486	Development and validation of a novel semi-homogenous clinical assay for quantitation of Ranibizumab in human serum. Journal of Immunological Methods, 2018, 461, 44-52.	1.4	11
487	Anti–Vascular Endothelial Growth Factor Therapy for Diabetic Eye Disease. , 2018, , 53-78.		1
488	Neovascular Ageâ€Related Macular Degeneration: A Visual Acuity Model of Natural Disease Progression and Ranibizumab Treatment Effect. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 660-669.	2.5	8
489	Platform development for expression and purification of stable isotope labeled monoclonal antibodies in <i>Escherichia coli</i> . MAbs, 2018, 10, 1-11.	5.2	8
490	Conbercept for patients with age-related macular degeneration: a systematic review. BMC Ophthalmology, 2018, 18, 142.	1.4	39
491	Theoretical Insights into the Retinal Dynamics of Vascular Endothelial Growth Factor in Patients Treated with Ranibizumab, Based on an Ocular Pharmacokinetic/Pharmacodynamic Model. Molecular Pharmaceutics, 2018, 15, 2770-2784.	4.6	32
492	Extended Duration Vascular Endothelial Growth Factor Inhibition in the Eye: Failures, Successes, and Future Possibilities. Pharmaceutics, 2018, 10, 21.	4.5	37
493	Short-term efficacy of intravitreal conbercept in treatment-naive patients with polypoidal choroidal vasculopathy. Drug Design, Development and Therapy, 2018, Volume 12, 339-345.	4.3	9
494	Comparison of Bevacizumab and Ranibizumab in the Treatment of Type 1 Retinopathy of Prematurity Affecting Zone 1. Ophthalmologica, 2018, 240, 99-105.	1.9	19

#	Article	IF	CITATIONS
495	Systemic side effects after intravitreal administration of antivascular endothelial growth factors for neovascular age-related macular degeneration. Spektrum Der Augenheilkunde, 2019, 33, 110-116.	0.3	0
496	Advances in the treatment of diabetic retinopathy. Journal of Diabetes and Its Complications, 2019, 33, 107417.	2.3	43
497	Antiâ€VEGFâ€Aptamer Modified Câ€Dots—A Hybrid Nanocomposite for Topical Treatment of Ocular Vascular Disorders. Small, 2019, 15, e1902776.	10.0	49
498	Short-term effects of anti-vascular endothelial growth factor on peripapillary choroid and choriocapillaris in eyes with neovascular age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology, 2019, 257, 2163-2172.	1.9	8
499	Clinical Changes after Switching from Ranibizumab/Aflibercept to Bevacizumab in Exudative Age-related Macular Degeneration. Journal of Korean Ophthalmological Society, 2019, 60, 40.	0.2	2
500	The effect of single dose adjunctive dexamethasone implant on diabetic macular edema in patients on anti-vascular endothelial growth factor treatment: 1 year follow-up from a real-life practice. Journal Francais D'Ophtalmologie, 2019, 42, 993-1000.	0.4	2
501	Aflibercept regulates retinal inflammation elicited by high glucose via the PIGF/ERK pathway. Biochemical Pharmacology, 2019, 168, 341-351.	4.4	57
502	Uptake of Ranibizumab but Not Bevacizumab into Uveal Melanoma Cells Correlates with a Sustained Decline in VEGF-A Levels and Metastatic Activities. Cancers, 2019, 11, 868.	3.7	9
503	Characterization of the internal translation initiation region in monoclonal antibodies expressed in Escherichia coli. Journal of Biological Chemistry, 2019, 294, 18046-18056.	3.4	8
505	Subclavian vein stent: Two decades of unassisted patency. Hemodialysis International, 2019, 23, 504-505.	0.9	0
506	Future perspectives of therapeutic monoclonal antibodies. Immunotherapy, 2019, 11, 119-127.	2.0	85
507	Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. Lancet, The, 2019, 394, 1551-1559.	13.7	268
508	Expression and Characterization of Human Vascular Endothelial Growth Factor Produced in SiHa Cells Transduced with Adenoviral Vector. Protein Journal, 2019, 38, 693-703.	1.6	3
509	Important Metabolites in Maintaining Folate Cycle, Homocysteine, and Polyamine Metabolism Associated with Ranibizumab Treatment in Cultured Human Tenon's Fibroblasts. Biomolecules, 2019, 9, 243.	4.0	0
510	Intravitreal ranibizumab versus aflibercept following treat and extend protocol for neovascular age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology, 2019, 257, 1671-1677.	1.9	13
511	Long-term changes in retinal layers in patients undergoing intravitreal ranibizumab for neovascular age-related macular degeneration. International Ophthalmology, 2019, 39, 2721-2730.	1.4	4
512	Effectiveness of monthly and fortnightly anti-VEGF treatments for age-related macular degeneration. Arquivos Brasileiros De Oftalmologia, 2019, 82, 225-232.	0.5	4
513	<p>Prefilled syringes for intravitreal drug delivery</p> . Clinical Ophthalmology, 2019, Volume 13, 701-706.	1.8	20

#	Article	IF	CITATIONS
514	Anti-vascular endothelial growth factor intravitreal therapy for retinopathy of prematurity. Seminars in Perinatology, 2019, 43, 375-380.	2.5	24
515	Vascular maturity of type 1 and type 2 choroidal neovascularization evaluated by optical coherence tomography angiography. PLoS ONE, 2019, 14, e0216304.	2.5	20
516	The results of aflibercept therapy as a first line treatment of age-related macular degeneration. Journal of Current Ophthalmology, 2019, 31, 66-71.	0.8	6
517	Shortâ€ŧerm effect on the ocular circulation induced by unilateral intravitreal injection of aflibercept in ageâ€ŧelated maculopathy. Acta Ophthalmologica, 2019, 97, e927-e932.	1.1	6
518	Safety and Efficacy of Anti-Vascular Endothelial Growth Factor Therapies for Neovascular Age-Related Macular Degeneration. Ophthalmology, 2019, 126, 55-63.	5.2	113
519	Conbercept for treatment of choroidal neovascularization secondary to pathologic myopia. Acta Ophthalmologica, 2019, 97, e813-e814.	1.1	13
520	Therapeutic targeting of angiogenesis molecular pathways in angiogenesis-dependent diseases. Biomedicine and Pharmacotherapy, 2019, 110, 775-785.	5.6	170
521	Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity. Graefe's Archive for Clinical and Experimental Ophthalmology, 2019, 257, 49-55.	1.9	46
522	Cluster endophthalmitis due to <i>Stenotrophomonas maltophilia</i> following intravitreal bevacizumab: outcomes of patients from North India. British Journal of Ophthalmology, 2019, 103, 1278-1283.	3.9	8
523	Vitreous and intraretinal macular changes in diabetic macular edema with and without tractional components. Graefe's Archive for Clinical and Experimental Ophthalmology, 2019, 257, 1-8.	1.9	22
524	Intravitreal ranibizumab versus laser photocoagulation for retinopathy of prematurity: efficacy, anatomical outcomes and safety. British Journal of Ophthalmology, 2019, 103, 1332-1336.	3.9	17
525	The short-term efficacy of intravitreal ranibizumab, aflibercept and dexamethasone implant in the treatment of macular edema due to non-ischemic central retinal vein occlusion. International Ophthalmology, 2019, 39, 891-901.	1.4	4
526	Intravitreal bevacizumab treatment for neovascular age-related macular degeneration and thromboembolic events. European Journal of Ophthalmology, 2020, 30, 66-71.	1.3	8
527	Effects of three intravitreal injections of aflibercept on the ocular circulation in eyes with age-related maculopathy. British Journal of Ophthalmology, 2020, 104, 53-57.	3.9	7
528	Retinal and choroidal cancers: Blood-retinal barriers considerations in ocular chemotherapy. , 2020, , 303-335.		4
530	Clinical Outcomes of a Treat and Extend Regimen with Intravitreal Aflibercept Injections in Patients with Diabetic Macular Edema: Experience in Clinical Practice. Ophthalmology and Therapy, 2020, 9, 87-101.	2.3	24
531	Sustained Elevation of Intraocular Pressure After Administration of Intravitreal Anti-Vascular Endothelial Growth Factor Agents in Patients With and Without Pseudoexfoliation Syndrome. Journal of Glaucoma, 2020, 29, 981-988.	1.6	3
532	Ranibizumab for myopic choroidal neovascularization. Expert Opinion on Biological Therapy, 2020, 20, 1385-1393.	3.1	14

#	Article	IF	CITATIONS
533	Sustained suppression of VEGF for treatment of retinal/choroidal vascular diseases. Progress in Retinal and Eye Research, 2021, 83, 100921.	15.5	57
534	Transport and fate of aflibercept in VEGF-A165-challenged retinal endothelial cells. Experimental Eye Research, 2020, 198, 108156.	2.6	5
535	Recent Developments in Agents for the Treatment of Age-Related Macular Degeneration and Stargardt Disease. Topics in Medicinal Chemistry, 2020, , 125-160.	0.8	3
536	Ranibizumab Population Pharmacokinetics and Free VEGF Pharmacodynamics in Preterm Infants With Retinopathy of Prematurity in the RAINBOW Trial. Translational Vision Science and Technology, 2020, 9, 43.	2.2	27
538	Formulation of nanoliposome-encapsulated bevacizumab (Avastin): Statistical optimization for enhanced drug encapsulation and properties evaluation. International Journal of Pharmaceutics, 2020, 590, 119895.	5.2	12
539	Ocular Pharmacokinetics and Drug Delivery Challenges. Topics in Medicinal Chemistry, 2020, , 43-81.	0.8	0
540	Structural Basis for Vascular Endothelial Growth Factor Receptor Activation and Implications for Disease Therapy. Biomolecules, 2020, 10, 1673.	4.0	43
541	<p>Multifocal ERG and Microperimetry Changes in Response to Ranibizumab Treatment of Neovascular AMD: Randomized Phase 2 Open-Label Study</p> . Clinical Ophthalmology, 2020, Volume 14, 3599-3610.	1.8	2
542	Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches. International Journal of Molecular Sciences, 2020, 21, 8242.	4.1	82
543	A Trinity regimen with aflibercept for treatment-naÃ⁻ve neovascular age-related macular degeneration: 2-year outcomes. Graefe's Archive for Clinical and Experimental Ophthalmology, 2020, 258, 1663-1670.	1.9	4
544	Current Approaches in Treatment of Diabetic Retinopathy and Future Perspectives. Journal of Ocular Pharmacology and Therapeutics, 2020, 36, 487-496.	1.4	15
545	Intraocular Distribution and Kinetics of Intravitreally Injected Antibodies and Nanoparticles in Rabbit Eyes. Translational Vision Science and Technology, 2020, 9, 20.	2.2	15
546	Macular atrophy after aflibercept therapy for neovascular age-related macular degeneration: outcomes of Japanese multicenter study. Japanese Journal of Ophthalmology, 2020, 64, 338-345.	1.9	9
547	A systematic review and meta-analysis to compare the efficacy of conbercept with ranibizumab in patients with macular edema secondary to retinal vein occlusion. Medicine (United States), 2020, 99, e20222.	1.0	7
548	Anatomical and functional responses in eyes with diabetic macular edema treated with "1 + PRN― ranibizumab: one-year outcomes in population of mainland China. BMC Ophthalmology, 2020, 20, 229.	1.4	5
549	<p>Therapeutic Potential of the Ranibizumab Port Delivery System in the Treatment of AMD: Evidence to Date</p> . Clinical Ophthalmology, 2020, Volume 14, 1349-1355.	1.8	30
550	Intravenous anti-VEGF agents with RGD peptide-targeted core cross-linked star (CCS) polymers modified with indocyanine green for imaging and treatment of laser-induced choroidal neovascularization. Biomaterials Science, 2020, 8, 4481-4491.	5.4	8
551	Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion. The Cochrane Library, 2020, 2020, CD009510.	2.8	20

#	ARTICLE	IF	Citations
552	a blunt adjustable depth injector. International Ophthalmology, 2020, 40, 2865-2874.	1.4	2
553	Correlation between anterior chamber flare changes and diabetic macular edema after intravitreal injection of ranibizumab and aflibercept. Japanese Journal of Ophthalmology, 2020, 64, 250-256.	1.9	7
554	One-year efficacy of intravitreal conbercept injection for macular oedema secondary to central retinal vein occlusion in Chinese patients. Eye, 2020, 34, 1459-1464.	2.1	6
555	Comparing the Efficacy of Bevacizumab and Ranibizumab in Patients with Retinal Vein Occlusion. Ophthalmology Retina, 2020, 4, 576-587.	2.4	12
556	Functional versus functional and anatomical criteria-guided ranibizumab treatment in patients with neovascular age-related macular degeneration – results from the randomized, phase IIIb OCTAVE study. BMC Ophthalmology, 2020, 20, 18.	1.4	8
557	A History of Anti-VEGF Inhibitors in the Ophthalmic Literature: A Bibliographic Review. Journal of Vitreoretinal Diseases, 2021, 5, 304-312.	0.7	0
558	INTRAVITREAL RANIBIZUMAB INJECTION AS TREATMENT IN PATIENTS WITH TYPE 1 RETINOPATHY OF PREMATURITY. , 2021, , 13-15.		0
559	Combined intravitreal ranibizumab and zone I sparing laser ablation in infants with posterior zone I retinopathy of prematurity. Indian Journal of Ophthalmology, 2021, 69, 2164.	1.1	10
560	Progress in the Treatment of Retinal Vein Obstructive Macular Edema. Advances in Clinical Medicine, 2021, 11, 3592-3598.	0.0	0
561	Evaluation of the Effects of Intravitreal Aflibercept and Ranibizumab on Systemic Inflammatory and Cardiovascular Biomarkers in Patients with Neovascular Age-related Macular Degeneration. Current Eye Research, 2021, 46, 1387-1392.	1.5	2
562	Intravitreal Therapy for Diabetic Macular Edema: An Update. Journal of Ophthalmology, 2021, 2021, 1-23.	1.3	27
563	Transient Ischemic Attack and Hypoventilation 12 Hours After Intra-vitreal Aflibercept Injection. Cureus, 2021, 13, e13488.	0.5	0
564	The Antiangiogenic Effect of Sanguinarine Chloride on Experimental Choroidal Neovacularization in Mice via Inhibiting Vascular Endothelial Growth Factor. Frontiers in Pharmacology, 2021, 12, 638215.	3.5	6
565	Cell Surface GRP94 as a Novel Emerging Therapeutic Target for Monoclonal Antibody Cancer Therapy. Cells, 2021, 10, 670.	4.1	20
566	Effects of Intravitreous Aflibercept Injection in Pachychoroid Neovasculopathy: Comparison with Typical Neovascular Age-Related Macular Degeneration. Clinical Ophthalmology, 2021, Volume 15, 1539-1549.	1.8	7
567	Anti-VEGF Drugs Influence Epigenetic Regulation and AMD-Specific Molecular Markers in ARPE-19 Cells. Cells, 2021, 10, 878.	4.1	9
568	Choroidal neovascularisation in a predicted female choroideraemia carrier treated with intravitreal anti-vascular endothelial growth factor. European Journal of Ophthalmology, 2021, 31, 4-10.	1.3	2
569	Nanotechnology: revolutionizing the delivery of drugs to treat age-related macular degeneration. Expert Opinion on Drug Delivery, 2021, 18, 1131-1149.	5.0	7

#	Article	IF	CITATIONS
570	New insights into oxidative stress and immune mechanisms involved in age-related macular degeneration tackled by novel therapies. Neuropharmacology, 2021, 188, 108513.	4.1	12
571	Ranibizumab for the treatment of diabetic retinopathy. Expert Opinion on Biological Therapy, 2021, 21, 991-997.	3.1	15
572	Efficacy and Safety of Biosimilar FYB201 Compared with Ranibizumab in Neovascular Age-Related Macular Degeneration. Ophthalmology, 2022, 129, 54-63.	5.2	30
573	Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review. International Journal of Retina and Vitreous, 2021, 7, 37.	1.9	53
574	Development of new therapeutic options for the treatment of uveal melanoma. FEBS Journal, 2021, 288, 6226-6249.	4.7	19
575	Role of bevacizumab intraocular injection in the management of neovascular glaucoma. International Journal of Ophthalmology, 2021, 14, 855-859.	1.1	1
576	Review of treatment and therapeutic targets in brain arteriovenous malformation. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 3141-3156.	4.3	18
577	Cytokine and Chemokine Profile Changes in Patients with Neovascular Age-Related Macular Degeneration After Intravitreal Ranibizumab Injection for Choroidal Neovascularization. Drug Design, Development and Therapy, 2021, Volume 15, 2457-2467.	4.3	4
578	Future Perspectives of Therapeutic, Diagnostic and Prognostic Aptamers in Eye Pathological Angiogenesis. Cells, 2021, 10, 1455.	4.1	4
579	Efficacy and Safety of Intravitreal Injection Ranibizumab versus Triamcinolone Acetonide in Diabetic Macular Oedema - A Prospective Randomized Study, Gorakhpur, Uttar Pradesh. Journal of Evidence Based Medicine and Healthcare, 2021, 8, 2444-2450.	0.0	0
580	Safety review of anti-VEGF therapy in patients with myopic choroidal neovascularization. Expert Opinion on Drug Safety, 2022, 21, 43-54.	2.4	9
581	Intravitreal Anti-Vascular Endothelial Growth Factor Agents for the Treatment of Diabetic Retinopathy: A Review of the Literature. Pharmaceutics, 2021, 13, 1137.	4.5	23
582	Molecular Features of Classic Retinal Drugs, Retinal Therapeutic Targets and Emerging Treatments. Pharmaceutics, 2021, 13, 1102.	4.5	8
583	Targeting the Angiopoietin/Tie Pathway: Prospects for Treatment of Retinal and Respiratory Disorders. Drugs, 2021, 81, 1731-1749.	10.9	9
584	Comparison of Efficacy and Safety between Conbercept and Ranibizumab in Neovascular Age-Related Macular Degeneration: A Meta-Analysis of Randomized Controlled Trials. Ophthalmic Research, 2022, 65, 140-151.	1.9	1
585	ABCA1 rs1883025 and CYP4F2 rs2108622 Gene Polymorphism Association with Age-Related Macular Degeneration and Anti-VEGF Treatment. Medicina (Lithuania), 2021, 57, 974.	2.0	2
586	Non-immediate drug hypersensitivity reactions secondary to intravitreal anti-vascular endothelial growth factors. Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, 260, 1005-1014.	1.9	1
587	Aflibercept clearance through the drainage system in a rat model. International Journal of Retina and Vitreous, 2021, 7, 53.	1.9	4

#	Article	IF	CITATIONS
588	Pipeline therapies for neovascular age related macular degeneration. International Journal of Retina and Vitreous, 2021, 7, 55.	1.9	21
589	Cloning and expression of antibody fragment (Fab) I: Effect of expression construct and induction strategies on light and heavy chain gene expression. Biochemical Engineering Journal, 2021, 176, 108189.	3.6	6
590	Ocular Drug Delivery to the Retina: Current Innovations and Future Perspectives. Pharmaceutics, 2021, 13, 108.	4.5	82
591	Fluorescein angiographic characteristic in predominantly classic and occult types of neovascular age-related macular degeneration treated with ranibizumab. Therapeutic Advances in Ophthalmology, 2021, 13, 251584142110053.	1.4	0
592	Long-term full-field and multifocal electroretinographic changes after treatment with ranibizumab in patients with diabetic macular edema. International Ophthalmology, 2021, 41, 1487-1501.	1.4	1
594	Overview and Clinical Applications of VEGF-A. , 2008, , 345-352.		2
595	Protein Drug Delivery and Formulation Development. AAPS Advances in the Pharmaceutical Sciences Series, 2011, , 409-448.	0.6	4
596	The Role of Inflammation in the Pathophysiology of Diabetic Retinopathy. , 2008, , 303-331.		4
597	The Role of the VEGF Signaling Pathway in Tumor Angiogenesis. , 2019, , 211-226.		5
598	Transscleral Drug Delivery to Retina and Posterior Segment Disease. , 2018, , 215-227.		2
599	Nucleic Acid Guided Molecular Tool for In-Vivo Theranostic Applications. , 2019, , 101-122.		1
600	Blockade of Tumor Necrosis Factor-Alpha: A Role for Adalimumab in Neovascular Age-Related Macular Degeneration Refractory to Anti-Angiogenesis Therapy. Case Reports in Ophthalmology, 2016, 7, 154-162.	0.7	15
601	Effects of Aflibercept for Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis of Observational Comparative Studies. , 2017, 58, 5616-5627.		24
602	Erythropoietin: when liability becomes asset in neurovascular repair. Journal of Clinical Investigation, 2008, 118, 467-70.	8.2	17
603	Ranibizumab versus Bevacizumab for Ophthalmic Diseases Related to Neovascularisation: A Meta-Analysis of Randomised Controlled Trials. PLoS ONE, 2014, 9, e101253.	2.5	9
604	Placenta Growth Factor in Eyes with Neovascular Glaucoma Is Decreased after Intravitreal Ranibizumab Injection. PLoS ONE, 2016, 11, e0146993.	2.5	7
605	The Vascular Endothelial Growth Factor Inhibitors Ranibizumab and Aflibercept Markedly Increase Expression of Atherosclerosis-Associated Inflammatory Mediators on Vascular Endothelial Cells. PLoS ONE, 2016, 11, e0150688.	2.5	24
606	Aqueous cytokine levels are associated with reduced macular thickness after intravitreal ranibizumab for diabetic macular edema. PLoS ONE, 2017, 12, e0174340.	2.5	19

#	Article	IF	CITATIONS
607	Preparation and in vitro characterization of monoclonal antibody ranibizumab conjugated magnetic nanoparticles for ocular drug delivery. Brazilian Journal of Pharmaceutical Sciences, 0, 56, .	1.2	7
608	Ranibizumab in Diabetic Macular Oedema – A Benefit–risk Analysis of Ranibizumab 0.5 mg PRN Versus Laser Treatment. European Endocrinology, 2017, 13, 91.	1.5	4
609	Comparison of conbercept and ranibizumab for the treatment efficacy of diabetic macular edema: a Meta-analysis and systematic review. International Journal of Ophthalmology, 2019, 12, 1479-1486.	1.1	11
610	Circulating insulin-like growth factor-1: a new clue in the pathogenesis of age-related macular degeneration. Aging, 2018, 10, 4241-4247.	3.1	9
611	Redox mechanisms in pathological angiogenesis in the retina: roles for NADPH oxidase. Current Pharmaceutical Design, 2015, 21, 5988-5998.	1.9	20
612	Pharmacokinetic and Pharmacodynamic Properties of Anti-VEGF Drugs After Intravitreal Injection. Current Drug Metabolism, 2015, 16, 572-584.	1.2	41
613	Clinical Risk Factors for Poor Anatomic Response to Ranibizumab in Neovascular Age-Related Macular Degeneration§. Open Ophthalmology Journal, 2014, 8, 3-6.	0.2	9
614	A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN). Health Technology Assessment, 2015, 19, 1-298.	2.8	62
615	Spectral-Domain OCT Analyses of Macular Changes After Ranibizumab Therapy for Type 1 Retinopathy of Prematurity. Journal of Pediatric Ophthalmology and Strabismus, 2015, 52, 152-158.	0.7	9
616	Treatment of Neovascular Age-Related Macular Degeneration with Pegaptanib and Boosting with Bevacizumab or Ranibizumab as Needed. Ophthalmic Surgery Lasers and Imaging Retina, 2008, 39, 294-298.	0.7	7
617	Computer-Assisted Image Processing for a Simulated Stereo Effect of Ocular Fundus and Fluorescein Angiography Photographs. Ophthalmic Surgery Lasers and Imaging Retina, 2010, 41, 293-300.	0.7	2
618	Ranibizumab for Eyes Previously Treated With Pegaptanib or Bevacizumab Without Clinical Response. Ophthalmic Surgery Lasers and Imaging Retina, 2012, 43, 13-19.	0.7	17
619	Bevacizumab Versus Ranibizumab in the Treatment of Macular Edema Due to Retinal Vein Occlusion: 6-Month Results of the CRAVE Study. Ophthalmic Surgery Lasers and Imaging Retina, 2015, 46, 844-850.	0.7	25
620	Comparison of Ranibizumab and Bevacizumab for Macular Edema Secondary to Retinal Vein Occlusions in Routine Clinical Practice. Ophthalmic Surgery Lasers and Imaging Retina, 2017, 48, 465-472.	0.7	11
621	Experimental Evidence Behind Clinical Trial Outcomes in Retinopathy of Prematurity. Ophthalmic Surgery Lasers and Imaging Retina, 2019, 50, 228-234.	0.7	6
622	Pharmacokinetics and distributions of bevacizumab by intravitreal injection of bevacizumab-PLGA microspheres in rabbits. International Journal of Ophthalmology, 2015, 8, 653-8.	1.1	22
623	Pegaptanib sodium for ocular vascular disease. Indian Journal of Ophthalmology, 2007, 55, 427.	1.1	25
624	A comparative debate on the various anti-vascular endothelial growth factor drugs: Pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin). Indian Journal of Ophthalmology, 2007, 55, 437.	1.1	29

#	Article	IF	CITATIONS
625	Updates on the clinical trials in diabetic macular edema. Middle East African Journal of Ophthalmology, 2016, 23, 3.	0.3	19
626	Current management strategy of polypoidal choroidal vasculopathy. Indian Journal of Ophthalmology, 2018, 66, 1727.	1.1	17
627	Real-world outcomes of intravitreal antivascular endothelial growth factors for neovascular age-related macular degeneration in Taiwan: A 4-year longitudinal study. Taiwan Journal of Ophthalmology, 2019, 9, 249.	0.7	4
628	Comparison of Combined Bevacizumab plus Dexamethasone Vs. Ranibizumab Monotherapy as First-Line Therapy in Patients with Treatment Naive Neovascular Age-Related Macular Degeneration in Real-Life Clinical Practice: A Retrospective Case-Series Analysis. Journal of Clinical & Experimental Ophthalmology, 2017, 08, .	0.1	1
629	Ranibizumab in diabetic macular edema. World Journal of Diabetes, 2013, 4, 310.	3.5	20
630	Mapping research trends of retinal vein occlusion from 2009 to 2018: a bibliometric analysis. PeerJ, 2019, 7, e7603.	2.0	12
631	Indocyanine Green Angiography in Age-Related Macular Degeneration. , 2007, , 177-194.		1
632	Tumor Endothelial Markers. , 2008, , 333-342.		Ο
633	Ranibizumab for Macular Edema Due to Retinal Vein Occlusions; Implication of VEGF as a Critical Stimulator. Molecular Therapy, 0, , .	8.2	2
634	Surgical choroidal neovascular membrane removal in the era of anti-vascular endothelial growth factor agents. Indian Journal of Ophthalmology, 2009, 57, 146.	1.1	0
635	Vascular Endothelial Growth Factor: Basic Biology and Clinical Applications. , 2009, , 11-21.		0
636	Combination Treatment for Choroidal Neovascularization Associated With Large Retinal Pigment Epithelial Detachment. Journal of Korean Ophthalmological Society, 2009, 50, 877.	0.2	0
639	Bevacizumab (Avastin) inhibits corneal neovascularization in rabbits. Academic Journal of Second Military Medical University, 2009, 29, 907-912.	0.0	0
640	Principales ensayos clÃnicos con fármacos anti-VEGF en la DMAE exudativa. , 2010, , 7-14.		0
641	Anti-VEGF-Therapie: Grundlagen und Substanzen. , 2011, , 229-236.		0
642	Anti-VEGF-Therapie der AMD: Ergebnisse und Leitlinien. , 2011, , 237-251.		0
643	VEGF Inhibitor Induced Oxidative Stress in Retinal Ganglion Cells. , 2012, , 585-593.		0
644	Fetal and Neonatal Illnesses Caused or Influenced by Maternal Transplacental IgG and/or Therapeutic Antibodies Applied During Pregnancy. , 2012, , 281-333.		0

# 645	ARTICLE Anti-VEGF Monotherapy Treatment Strategies for Neovascular AMD. , 2012, , 479-499.	IF	CITATIONS
646	Neovascular Age-Related Macular Degeneration: Rationale for Current Treatment Guidelines. Essentials in Ophthalmology, 2013, , 107-125.	0.1	0
647	Efficacy and Safety of Ranibizumab Intravitreal Injections versus Laser Photocoagulation in Patients with Diabetic Macular Edema. American Journal of Pharmacological Sciences, 2014, 2, 72-76.	0.2	0
648	A Long-Term Study of Efficacy of Patients with Macular Edema Secondary to BRVO Treated with Ranibizumab Combined with Compound Salvia. Chinese Medicine, 2015, 06, 169-174.	0.3	0
650	Lucentis® (Ranibizumab Ophthalmic Injection) for Diabetic Macular Edema (DME). Pharmacy & Pharmacology International Journal, 2016, 4, .	0.2	0
652	DİYABETİK MAKULA ĖDEMİNİN FARMAKOLOJİK YĖNETİMİNDE GŜNCEL GELİŞMELER: İNTRA UYGULAMALARI VE SĜREKLİ İLAć SALINIM SİSTEMLERİ. Kocatepe Tıp Dergisi, 2017, 18, 37-43.	VİTREAL 0.1	ENJEKSİYC
653	Anti-angiogenesis Therapy in Diabetic Retinopathy. , 2017, , 299-323.		0
654	Efficiency and safety of laser photocoagulation with or without intravitreal ranibizumab for treatment of diabetic macular edema: a systematic review and Meta-analysis. International Journal of Ophthalmology, 2017, 10, 1134-1143.	1.1	4
657	The Role of the VEGF Signaling Pathway in Tumor Angiogenesis. , 2019, , 1-16.		0
658	Combined Treatment with Intravitreal Bevacizumab and Intravitreal Triamcinolone in Retinal Vein Occlusion in Indian Eyes. Journal of Postgraduate Medicine Education and Research, 2019, 53, 75-78.	0.1	1
659	Intravitreal injections in veterinary ophthalmology: literature review. Russian Veterinary Journal, 2019, 2019, 6-12.	0.2	0
660	EFFECT OF SINGLE DOSE OF INTRAVITREAL RANIBIZUMAB INJECTION FOLLOWED BY TRABECULECTOMY WITH MITOMYCIN-C IN CASES OF NEOVASCULAR GLAUCOMA WITH HAZY MEDIA OBSCURING PRP IN A PERIPHERAL MEDICAL COLLEGE IN WEST BENGAL. Journal of Evolution of Medical and Dental Sciences, 2019, 8, 2255-2259.	0.1	0
661	Effect of Drugs and Nanoformulation on Ocular Cells in Various Disease States. , 2020, , 259-283.		1
662	Characterization of Antineovascularization Activity and Ocular Pharmacokinetics of Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GNE-947. Drug Metabolism and Disposition, 2020, 48, 408-419.	3.3	5
663	Yaş Tip Senil Maküla Dejeneresansı Olan Hastalarda İntravitreal Enjeksiyonun Okülokardiak Refleks Üzerine Etkisi. Dicle Medical Journal, 0, , 202-207.	0.6	0
666	Novel Therapeutic Strategies For Posterior Segment Neovascularization. , 2008, , 445-526.		0
667	Neutralizing antibody to VEGF reduces intravitreous neovascularization and may not interfere with ongoing intraretinal vascularization in a rat model of retinopathy of prematurity. Molecular Vision, 2008, 14, 345-57.	1.1	58
668	Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes. Molecular Vision, 2008, 14, 997-1005.	1.1	41

#	Article	IF	CITATIONS
669	A reproducible and quantifiable model of choroidal neovascularization induced by VEGF A165 after subretinal adenoviral gene transfer in the rabbit. Molecular Vision, 2008, 14, 1358-72.	1.1	20
670	Alternate serotype adenovector provides long-term therapeutic gene expression in the eye. Molecular Vision, 2008, 14, 2535-46.	1.1	22
671	Inhibition of choroidal neovascularization by topical application of angiogenesis inhibitor vasostatin. Molecular Vision, 2009, 15, 1897-905.	1.1	10
672	Studies on the pathogenesis of avascular retina and neovascularization into the vitreous in peripheral severe retinopathy of prematurity (an american ophthalmological society thesis). Transactions of the American Ophthalmological Society, 2010, 108, 96-119.	1.4	33
673	The influence of genetics on response to treatment with ranibizumab (Lucentis) for age-related macular degeneration: the Lucentis Genotype Study (an American Ophthalmological Society thesis). Transactions of the American Ophthalmological Society, 2011, 109, 115-56.	1.4	36
674	Nano chitosan peptide as a potential therapeutic carrier for retinal delivery to treat age-related macular degeneration. Molecular Vision, 2012, 18, 2300-8.	1.1	23
675	Choroidal neovascularization reduced by targeted drug delivery with cationic liposome-encapsulated paclitaxel or targeted photodynamic therapy with verteporfin encapsulated in cationic liposomes. Molecular Vision, 2013, 19, 54-61.	1.1	31
676	Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis). Transactions of the American Ophthalmological Society. 2014. 112. 160-98.	1.4	20
677	Bevacizumab versus ranibizumab for neovascular age-related macular degeneration: a Meta-analysis. International Journal of Ophthalmology, 2015, 8, 138-47.	1.1	6
678	Association of gene polymorphism with serum levels of inflammatory and angiogenic factors in Pakistani patients with age-related macular degeneration. Molecular Vision, 2015, 21, 985-99.	1.1	23
680	Acquired perforating collagenosis associated with ranibizumab injection and succesfully switched to aflibercept. GMS Ophthalmology Cases, 2018, 8, Doc06.	0.1	2
681	Oculocardiac Reflex During Intravitreal Injection. Medical Hypothesis, Discovery, and Innovation in Ophthalmology, 2020, 9, 111-117.	0.2	3
682	Expression of functional eGFP-fused antigen-binding fragment of ranibizumab in Pichia pastoris. Biolmpacts, 2021, , .	1.5	1
683	Retinal and Choroidal Vascular Diseases: Past, Present, and Future: The 2021 Proctor Lecture. , 2021, 62, 26.		6
684	Factors for Visual Acuity Improvement After Anti-VEGF Treatment of Wet Age-Related Macular Degeneration in China: 12 Months Follow up. Frontiers in Medicine, 2021, 8, 735318.	2.6	6
685	Targeting Ocular Drug Delivery: An Examination of Local Anatomy and Current Approaches. Bioengineering, 2022, 9, 41.	3.5	24
686	Current Management of Diabetic Macular Edema. , 0, , .		1
687	Blocking of VEGF-A is not sufficient to completely revert its long-term effects on the barrier formed by retinal endothelial cells. Experimental Eye Research, 2022, 216, 108945.	2.6	6

		CITATION REPORT		
#	ARTICLE Antibodyâ€Incorporated Nanomedicines for Cancer Therapy, Advanced Materials, 2022	34 e2109210	IF 21.0	CITATIONS
690	In-vitro characterization of ranibizumab release from the Port Delivery System. Journal of Pelase 2022, 345, 101-107	of Controlled	9.9	11
691	VEGF-targeting drugs for the treatment of retinal neovascularization in diabetic retinop of Medicine, 2022, 54, 1089-1111.	athy. Annals	3.8	37
694	Biomarkers as Predictive Factors of Anti-VEGF Response. Biomedicines, 2022, 10, 1003		3.2	12
695	Current Status and Challenges of Aptamers Screening and Optimization. Combinatoria High Throughput Screening, 2023, 26, 1067-1082.	Chemistry and	1.1	1
696	Dry Eye and Meibomian Gland Dysfunction in Neovascular Age-Related Macular Degene Treated with Intravitreal Injections. Türk Oftalmoloji Dergisi, 2022, 52, 157-161.	ration Patients	0.9	3
697	SIRT1: Genetic Variants and Serum Levels in Age-Related Macular Degeneration. Life, 20	)22, 12, 753.	2.4	0
698	Genetic Association Analysis of Anti-VEGF Treatment Response in Neovascular Age-Rela Degeneration. International Journal of Molecular Sciences, 2022, 23, 6094.	ted Macular	4.1	3
699	Differences in Vitreous Protein Profiles in Patients With Proliferative Diabetic Retinopat and After Ranibizumab Treatment. Frontiers in Medicine, 2022, 9, .	hy Before	2.6	1
700	Towards the Development of Longer and More Efficacious Therapies for Wet and Dry A Macular Degeneration. , 2022, 16, 30.	ge-related		0
701	Pharmacokinetics of the Port Delivery System with Ranibizumab in the Ladder Phase 2 Neovascular Age-Related Macular Degeneration. Ophthalmology and Therapy, 2022, 11	Frial for ., 1705-1717.	2.3	9
702	Efficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy: what we ha what should we learn further?. Expert Opinion on Biological Therapy, 2022, 22, 1275-12	ve learned and 291.	3.1	18
704	Beovu, but not Lucentis impairs the function of the barrier formed by retinal endothelia vitro. Scientific Reports, 2022, 12, .	l cells in	3.3	0
706	Age-related macular degeneration and its treatment options. , 2022, , 333-342.			0
707	Therapeutic Human Monoclonal Antibodies. , 2022, , 401-418.			1
708	Progress and Challenges of Anti-VEGF Agents and Their Sustained-Release Strategies fo Angiogenesis. Drug Design, Development and Therapy, 0, Volume 16, 3241-3262.	r Retinal	4.3	17
709	RNAapt3D: RNA aptamer 3D-structural modeling database. Biophysical Journal, 2022, ,		0.5	1
710	A Linkage between Angiogenesis and Inflammation in Neovascular Age-Related Macular Cells, 2022, 11, 3453.	Degeneration.	4.1	16

#	Article	IF	CITATIONS
711	Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Oedema: Is It Safe?. European Medical Journal Diabetes, 0, , 126-133.	4.0	1
712	Current and Novel Therapeutic Approaches for Treatment of Neovascular Age-Related Macular Degeneration. Biomolecules, 2022, 12, 1629.	4.0	20
713	Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS). Frontiers in Pharmacology, 0, 13, .	3.5	6
715	Faricimab in the Treatment Landscape for Retinal Diseases: A Review. , 2022, 16, 92.		0
716	Resveratrol: Its Path from Isolation to Therapeutic Action in Eye Diseases. Antioxidants, 2022, 11, 2447.	5.1	5
717	A Review of Neovascular Glaucoma: Etiology, Pathogenesis, Diagnosis, and Treatment. Medicina (Lithuania), 2022, 58, 1870.	2.0	4
718	Assessment of mouse VEGF neutralization by ranibizumab and aflibercept. PLoS ONE, 2022, 17, e0278951.	2.5	1
719	Endpoints for clinical trials in ophthalmology. Progress in Retinal and Eye Research, 2023, 97, 101160.	15.5	10
720	Polypoidal Choroidal Vasculopathy: An Update on Diagnosis and Treatment. Clinical Ophthalmology, 0, Volume 17, 53-70.	1.8	8
721	Treatment Strategies for Chorioretinal Vascular Diseases: Advantages and Disadvantages of Individualised Therapy. European Medical Journal Diabetes, 0, , 91-98.	4.0	0
722	Role of Oxidative Stress in Ocular Diseases: A Balancing Act. Metabolites, 2023, 13, 187.	2.9	16
724	Anti-Angiogenic Activity of Drugs in Multiple Myeloma. Cancers, 2023, 15, 1990.	3.7	2
725	Biosimilar versus InnovAtor MoLecule of RAnibizumab in Neovascular Age-Related MaCular DEgeneration (The BALANCE Trial): Real-World Evidence. Clinical Ophthalmology, 0, Volume 17, 1067-1076.	1.8	4
726	Targeting angiogenesis in oncology, ophthalmology and beyond. Nature Reviews Drug Discovery, 2023, 22, 476-495.	46.4	43
727	Topical bromfenac as adjunctive treatment with intravitreal ranibizumab for diabetic macular edema. International Ophthalmology, 2023, 43, 3219-3226.	1.4	0
728	Protein Therapeutics and Blinding Diseases. , 2017, , 174-195.		0
729	High‑dose aflibercept injection has striking effects on myopic choroidal neovascularization. Experimental and Therapeutic Medicine, 2023, 25, .	1.8	0
730	Short-term outcomes of intravitreal faricimab for treatment-naÃ⁻ve neovascular age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology, 2023, 261, 2945-2952.	1.9	11

#	Article	IF	CITATIONS
731	Population Pharmacokinetics of Ranibizumab Delivered via the Port Delivery System Implanted in the Eye in Patients with Neovascular Ageâ€Related Macular Degeneration. Journal of Clinical Pharmacology, 2023, 63, 1210-1220.	2.0	1
732	Intravitreal Therapy for Uveitic Macular Edema—Ranibizumab versus Methotrexate versus the Dexamethasone Implant. Ophthalmology, 2023, 130, 914-923.	5.2	2
733	Systematic review of efficacy and meta-analysis of safety of ranibizumab biosimilars relative to reference ranibizumab anti-VEGF therapy for nAMD treatment. BMJ Open Ophthalmology, 2023, 8, e001205.	1.6	1
734	Rethinking the potential and necessity of drug delivery systems in neovascular age-related macular degeneration therapy. Frontiers in Bioengineering and Biotechnology, 0, 11, .	4.1	0
736	Current Treatments for Diabetic Macular Edema. International Journal of Molecular Sciences, 2023, 24, 9591.	4.1	3
737	Biology and therapeutic targeting of vascular endothelial growth factor A. Nature Reviews Molecular Cell Biology, 2023, 24, 816-834.	37.0	28
738	The evolving therapeutic landscape of diabetic retinopathy. Expert Opinion on Biological Therapy, 2023, 23, 969-985.	3.1	2
739	Revisiting Retinal Degeneration Hallmarks: Insights from Molecular Markers and Therapy Perspectives. International Journal of Molecular Sciences, 2023, 24, 13079.	4.1	0
740	Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology, 2024, 262, 43-51.	1.9	2
741	Current design and advances of hydrogel for retinal tissue engineering and regenerative medicine. , 2024, , 691-724.		0
742	From randomised controlled trials to real-world data: Clinical evidence to guide management of diabetic macular oedema. Progress in Retinal and Eye Research, 2023, 97, 101219.	15.5	1
743	Recent advances of anti-angiogenic inhibitors targeting VEGF/VEGFR axis. Frontiers in Pharmacology, 0, 14, .	3.5	0
744	One-year results of treat-and-extend regimen with intravitreal faricimab for treatment-naÃ <sup>-</sup> ve neovascular age-related macular degeneration. Japanese Journal of Ophthalmology, 2024, 68, 83-90.	1.9	0
745	Progress of anti-vascular endothelial growth factor therapy for ocular neovascular disease: benefits and challenges. Chinese Medical Journal, 2014, 127, 1550-1557.	2.3	2
746	Comparison of antiangiogenic agents (ranibizumab, aflibercept, bevacizumab and ziv-aflibercept) in the therapeutic response to the exudative form of age-related macular degeneration according to the treat-and-extend protocol- true head-to-head study. International Journal of Retina and Vitreous, 2024, 10, .	1.9	0
747	Age-associated macular degeneration: Epidemiologic features, complications, and potential therapeutic approaches. , 2024, , 381-429.		0
748	Ranibizumab Biosimilars in Treating Retinal Disorders: A Cost-Effective Revolution?. Drug Design, Development and Therapy, 0, Volume 18, 365-374.	4.3	0
749	Macular Oedema. , 2023, , 271-317.		0

#	Article	IF	CITATIONS
750	Retinal Vascular Occlusions. , 2023, , 179-203.		0
751	Impact of Nintedanib and Anti-Angiogenic Agents on Uveal Melanoma Cell Behavior. , 2024, 65, 30.		0
752	Thrombospondin-1, BIM and CFH polymorphisms and response to anti-VEGF treatment in neovascular age- related macular degeneration patients. PLoS ONE, 2024, 19, e0297135.	2.5	0
753	Management of treatment-naÃ <sup>-</sup> ve diabetic macular edema patients: Review of real-world clinical data. European Journal of Ophthalmology, 0, , .	1.3	0